<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Sertraline: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Sertraline: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Sertraline: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9886" href="/d/html/9886.html" rel="external">see "Sertraline: Drug information"</a> and <a class="drug drug_patient" data-topicid="11044" href="/d/html/11044.html" rel="external">see "Sertraline: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709410"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Suicidality and antidepressant drugs:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants increased the risk of suicidal thoughts and behavior in pediatric and young adult patients in short-term studies. Closely monitor all antidepressant-treated patients for clinical worsening, and for emergence of suicidal thoughts and behaviors.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F220684"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Zoloft</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F57397473"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>AG-Sertraline;</li>
<li>APO-Sertraline;</li>
<li>Auro-Sertraline;</li>
<li>BIO-Sertraline;</li>
<li>DOM-Sertraline;</li>
<li>JAMP-Sertraline [DSC];</li>
<li>M-Sertraline;</li>
<li>Mar-Sertraline;</li>
<li>MINT-Sertraline;</li>
<li>NRA-Sertraline;</li>
<li>PMS-Sertraline;</li>
<li>Priva-Sertraline [DSC];</li>
<li>RAN-Sertraline [DSC];</li>
<li>RIVA-Sertraline;</li>
<li>SANDOZ Sertraline [DSC];</li>
<li>TEVA-Sertraline;</li>
<li>Zoloft</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1055426"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Antidepressant, Selective Serotonin Reuptake Inhibitor (SSRI)</span></li></ul></div>
<div class="block dop drugH1Div" id="F220706"><span class="drugH1">Dosing: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Two solid oral dosage forms are available (tablets and capsules); the capsules are available in two strengths (150 mg and 200 mg) and should not be used to initiate sertraline therapy. Capsules may be considered in patients who have received sertraline 100 or 125 mg daily for at least 1 week.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ae35da88-7e3c-40ea-9daa-1be1ccfd22b6">Depression</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Depression:</b> Limited data available:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In the management of pediatric depression in children and adolescents, if pharmacotherapy deemed necessary with/without psychotherapeutic interventions, a selective serotonin reuptake inhibitor (SSRI) is recommended first line; sertraline is not typically recommended first line due to the availability of 2 SSRIs with FDA-approval for pediatric depression (fluoxetine, escitalopram); in practice, sertraline is often an alternative or subsequent medication early in pediatric depression treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29483201','lexi-content-ref-APA.1','lexi-content-ref-31577402']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29483201','lexi-content-ref-APA.1','lexi-content-ref-31577402'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥6 years and Adolescents ≤17 years: Oral: Initial: 25 mg once daily; titrate in 12.5 to 25 mg increments at ≥1-week intervals; usual effective dose: 50 mg once daily; maximum daily dose: 200 mg/<b>day</b>; consider lower initial dose of 12.5 mg in patients who are sensitive to the higher 25 mg dose. For acute treatment in an inpatient setting and as an initial therapy, a more rapid dose titration may be considered with close monitoring (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29483201','lexi-content-ref-16434782','lexi-content-ref-12941675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29483201','lexi-content-ref-16434782','lexi-content-ref-12941675'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5359f530-bf85-41b9-82bc-913f7d455fcc">Obsessive-compulsive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder (OCD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> In the management of OCD in children and adolescents, if pharmacotherapy deemed necessary it should be in combination with cognitive behavior therapy (CBT) and an SSRI should be used first line; a preferred agent has not been identified (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22176943','lexi-content-ref-15507582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22176943','lexi-content-ref-15507582'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 12 years: Oral: Initial: 25 mg once daily; titrate dose upwards if clinically needed; increase by 25 to 50 mg/day increments at intervals of at least 1 week; range: 25 to 200 mg/day; maximum daily dose: 200 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">Adolescents 13 to 17 years: Oral: Initial: 50 mg once daily; titrate dose upwards if clinically needed; increase by 50 mg/day increments at intervals of at least 1 week; range: 25 to 200 mg/day; maximum daily dose: 200 mg/<b>day</b>.</p>
<p style="text-indent:-2em;margin-left:4em;">When combined with CBT, the 12-week Pediatric OCD Treatment Study (POTS) Randomized Controlled Trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15507582']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15507582'])">Ref</a></span>), which included 97 patients (age range: 7 to 17 years), reported mean highest daily sertraline doses of 133 ± 64 mg in the sertraline/CBT group, 170 ± 33 mg in the sertraline-only group, and 176 ± 40 mg for the group who received placebo equivalents; median doses were 150, 200, and 200 mg, respectively. Dosing used a fixed flexible upward titration from 25 mg/day to 200 mg/day over 6 weeks, after which the dosage could be adjusted based on adverse effects only.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Consider planning antidepressant discontinuation for lower-stress times, recognizing non-illness-related factors could cause stress or anxiety and be misattributed to antidepressant discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29337001']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29337001'])">Ref</a></span>). Upon discontinuation of antidepressant therapy, gradually taper the dose to minimize the incidence of discontinuation syndromes (withdrawal) and allow for the detection of reemerging disease state symptoms (eg, relapse). Evidence supporting ideal taper rates after illness remission is limited. APA and NICE guidelines suggest tapering therapy over at least several weeks with consideration to the half-life of the antidepressant; antidepressants with a shorter half-life may need to be tapered more conservatively. After long-term (years) antidepressant treatment, WFSBP guidelines recommend tapering over 4 to 6 months, with close monitoring during and for 6 months after discontinuation. If intolerable discontinuation symptoms occur following a dose reduction, consider resuming the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-12479080','lexi-content-ref-19621834','lexi-content-ref-11347722','lexi-content-ref-22132433','lexi-content-ref-16683860','lexi-content-ref-15014601','lexi-content-ref-16913164'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Switching antidepressants:</b> Evidence for ideal antidepressant switching strategies in pediatric patients is sparse; strategies described in pediatric guidelines include a conservative approach (tapering and discontinuing the first SSRI before adding the second) and cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant). While consensus does not exist regarding which approach to utilize, it is important to note that the conservative approach runs the risk for exacerbation of symptoms or discontinuation syndrome; cross-titration may avoid these risks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32439401']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32439401'])">Ref</a></span>). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from a monamine oxidase inhibitors. While not as common of a strategy, a direct switch may be considered when switching to another agent in the same or similar class (eg, when switching between 2 SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51159989"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in manufacturer's labeling; however, sertraline pharmacokinetics does not appear to be affected by renal impairment.</p></div>
<div class="block dohp drugH1Div" id="F51159990"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children ≥6 years and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild impairment: Reduce dose to 50% of usual dose.</p>
<p style="text-indent:-2em;margin-left:4em;">Moderate to severe impairment: Use is not recommended.</p></div>
<div class="block doa drugH1Div" id="F220689"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9886" href="/d/html/9886.html" rel="external">see "Sertraline: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosing:</b> Some experts suggest a lower starting dose of 12.5 to 25 mg daily and gradual titration in increments of ≤25 mg, particularly in patients with anxiety who are sensitive to antidepressant-associated overstimulation effects (eg, anxiety, insomnia) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2018a','lexi-content-ref-Stein.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2018a','lexi-content-ref-Stein.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Dosage form information: </b>Do not initiate treatment with capsules; administer other sertraline products for initial dosage, titration, and doses &lt;150 mg once daily; however, capsules may be initiated in patients who have received sertraline 100 or 125 mg for ≥1 week or sertraline ≥150 mg/day.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d98a9598-5db0-4f0c-a3c4-96cdecc00d76">Binge eating disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Binge eating disorder (off-label use):</b>
<b>Oral:</b> Initial: 25 mg once daily after lunch; may increase dose based on response and tolerability in increments of 25 mg every 3 days. Usual dose range: 100 to 200 mg/day. Maximum dose: 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18598735']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18598735'])">Ref</a></span>). Based on limited data, some experts recommend doses used for major depressive disorder and slower titrations (eg, ≥1 week) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Sysko.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Sysko.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="88be5c8f-c670-41f5-94ab-670c50aba438">Body dysmorphic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Body dysmorphic disorder (BDD) (off-label use):</b>
<b>Oral:</b> Some experts suggest an initial dose of 50 mg once daily; may increase dose gradually based on response and tolerability in increments of 25 to 50 mg at intervals of every 2 to 3 weeks up to a usual dose of 200 mg/day; doses up to 400 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Phillips.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Phillips.2019'])">Ref</a></span>). <b>Note:</b> An adequate trial for assessment of effect in BDD is 12 to 16 weeks, including maximum tolerated doses for at least 3 to 4 of those weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Phillips.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Phillips.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="09d5012d-4c68-41f6-9a1f-54da08b78eeb">Bulimia nervosa</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Bulimia nervosa (alternative agent) (off-label use):</b>
<b>Oral:</b> Initial: 50 mg daily; may increase dose based on response and tolerability in increments of 50 mg at intervals ≥1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15605617','lexi-content-ref-15185271']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15605617','lexi-content-ref-15185271'])">Ref</a></span>). Maximum dose: 300 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Crow.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Crow.2019'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="3acdc9e2-eb5e-47b3-8f22-12bd8ae32922">Generalized anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Generalized anxiety disorder (GAD) (off-label use):</b>
<b>Oral:</b> Initial: 25 to 50 mg once daily. If initiating with 25 mg/day, may increase to 50 mg/day after 1 week or sooner (after 3 to 4 days) based on tolerability. May then increase dose based on response and tolerability in increments of 25 to 50 mg per day at intervals ≥1 week. In contrast, some experts maintain the dose at 25 to 50 mg/day for 4 to 6 weeks to assess for efficacy before increasing further. Usual dose: 50 to 150 mg/day. Maximum dose: 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16848646','lexi-content-ref-Craske.1','lexi-content-ref-15877709']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16848646','lexi-content-ref-Craske.1','lexi-content-ref-15877709'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="cf110575-e58e-40d7-bc64-ed5b385ce732">Major depressive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Major depressive disorder (MDD) (unipolar):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablets, oral solution:</b>
<b>Oral:</b> Initial: 50 mg once daily; may increase dose based on response and tolerability in increments of 25 to 50 mg once weekly to a maximum of 200 mg/day (according to manufacturer's labeling); however, doses up to 300 mg/day have been used in clinical practice for MDD and may provide further benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Simon.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Simon.2016'])">Ref</a></span>). More rapid titrations (every 3 days) in combination with an antipsychotic (eg, olanzapine) are used by some experts for patients with psychotic features (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19652123','lexi-content-ref-Rothschild.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19652123','lexi-content-ref-Rothschild.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Capsules:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Capsules may be initiated in patients receiving sertraline 100 mg/day or 125 mg/day for ≥1 week or sertraline ≥150 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Usual dose: 150 or 200 mg once daily. Maximum dose: 200 mg/day; however, doses up to 300 mg/day have been used in clinical practice for MDD and may provide further benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Simon.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Simon.2016'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="5359f530-bf85-41b9-82bc-913f7d455fcc">Obsessive-compulsive disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Obsessive-compulsive disorder:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Tablets, oral solution: Oral:</b> Initial: 50 mg once daily; may increase dose based on response and tolerability in increments of 25 to 50 mg once weekly to a maximum of 200 mg/day (according to the manufacturer's labeling). Doses up to 400 mg/day may have modest clinical benefit in patients with inadequate response to standard doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16426083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16426083'])">Ref</a></span>), but adverse effects may be increased.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Capsules:</b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note: </b>Capsules may be initiated in patients receiving sertraline 100 mg/day or 125 mg/day for ≥1 week or sertraline ≥150 mg/day.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Usual dose: 150 mg or 200 mg once daily. Maximum dose: 200 mg/day. Doses up to 400 mg/day may have modest clinical benefit in patients with inadequate response to standard doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16426083']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16426083'])">Ref</a></span>), but adverse effects may be increased.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="35322c81-c95a-4c47-baaf-72001a1c63ee">Panic disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Panic disorder:</b>
<b>Oral:</b> Initial: 25 mg once daily for 3 to 7 days, then increase to 50 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2018'])">Ref</a></span>); thereafter, may increase dose based on response and tolerability in increments of 25 to 50 mg at intervals ≥1 week to a maximum of 200 mg/day.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="33aa39f3-80b9-497a-8725-78dfd54c167a">Posttraumatic stress disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Posttraumatic stress disorder (PTSD):</b>
<b>Oral:</b> Initial: 25 to 50 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-VADod.2017']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-VADod.2017'])">Ref</a></span>); may increase dose based on response and tolerability in increments of 25 to 50 mg at intervals ≥1 week to a maximum of 200 mg/day (according to the manufacturer's labeling); however, doses up to 250 mg/day have been used in clinical practice and may provide further benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.2018']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.2018'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="03008e1c-e898-491f-b522-256bb5260378">Premature ejaculation</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Premature ejaculation (off-label use):</b>
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Daily dosing: Initial: 50 mg once daily; may increase dose based on response and tolerability at intervals of ~3 to 4 weeks in 50 mg increments up to 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9788108','lexi-content-ref-8830065']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9788108','lexi-content-ref-8830065'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">On-demand dosing: Based on limited evidence: 100 mg 6 to 8 hours before intercourse; maximum dose 2 times per week, with ≥3 days between doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33113277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33113277'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c36dd6b3-72d8-44c0-9113-9b954af8885b">Premenstrual dysphoric disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Premenstrual dysphoric disorder (PMDD):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Continuous daily dosing regimen:</i></b>
<b>Oral:</b> Initial: 25 mg once daily; over the first month, increase to the usual effective dose of 50 mg once daily; in subsequent menstrual cycles, further increases in dose (eg, in 50 mg increments per menstrual cycle) up to 200 mg/day may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Intermittent regimens: </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Luteal phase dosing regimen:</i>
<b>Oral:</b> Initial: 25 mg once daily during the luteal phase of menstrual cycle only (ie, beginning therapy 14 days before anticipated onset of menstruation and continued to the onset of menses); over the first month, increase to the usual effective dose of 50 mg/day; in subsequent menstrual cycles, further increases in dose (eg, in 50 mg increments per menstrual cycle) up to 150 mg/day during the luteal phase may be necessary in some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>Symptom-onset dosing regimen (off-label dosing):</i>
<b>Oral:</b> Initial: 25 mg once daily from the day of symptom onset until a few days after the start of menses; over the first month, increase to the usual effective dose of 50 mg/day; in subsequent menstrual cycles, further increases in dose (eg, in 50 mg increments per menstrual cycle) up to 150 mg/day may be necessary for some patients for optimal response (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Casper.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Casper.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> If a daily dose ≥100 mg was established in previous cycles, may begin with 50 mg once daily for 2 to 3 days in subsequent cycles, then increase to previously established dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26351969','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26351969','lexi-content-ref-manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="24aa5a69-6727-4715-b53a-79a3f9ae11c6">Social anxiety disorder</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Social anxiety disorder:</b>
<b>Oral:</b> Initial: 25 to 50 mg once daily; after ~6 weeks, may increase dose based on response and tolerability in increments of 25 to 50 mg at intervals ≥1 week to a maximum of 200 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-35900161','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-35900161','lexi-content-ref-manu.1'])">Ref</a></span>); however, doses up to 250 mg/day have been used in clinical practice and may provide further benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Stein.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Stein.2019'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Discontinuation of therapy:</b></i> Due to its prolonged half-life (parent and active metabolite), withdrawal symptoms are typically not observed after abrupt discontinuation; however, tapering should still be considered to assess for symptom reoccurrence. When discontinuing antidepressant treatment that has lasted for &gt;3 weeks, gradually taper the dose (eg, over 2 to 4 weeks) to minimize withdrawal symptoms and detect reemerging symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-25677972'])">Ref</a></span>). Reasons for a slower taper (eg, over 4 weeks) include prior history of antidepressant withdrawal symptoms or high doses of antidepressants (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019'])">Ref</a></span>). If intolerable withdrawal symptoms occur, resume the previously prescribed dose and/or decrease dose at a more gradual rate (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601'])">Ref</a></span>). Select patients (eg, those with a history of discontinuation syndrome) on long-term treatment (&gt;6 months) may benefit from tapering over &gt;3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25677972'])">Ref</a></span>). Evidence supporting ideal taper rates is limited (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15014601','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15014601','lexi-content-ref-25677972'])">Ref</a></span>). When tapering the dose of sertraline capsules, doses &lt;150 mg will require the use of another sertraline product.</p>
<p style="text-indent:-2em;margin-left:2em;">
<i>
<b>Switching</b>
<b> antidepressants: </b></i>Evidence for ideal antidepressant switching strategies is limited; strategies include cross-titration (gradually discontinuing the first antidepressant while at the same time gradually increasing the new antidepressant) and direct switch (abruptly discontinuing the first antidepressant and then starting the new antidepressant at an equivalent dose or lower dose and increasing it gradually). Cross-titration (eg, over 1 to 4 weeks depending upon sensitivity to discontinuation symptoms and adverse effects) is standard for most switches, but is contraindicated when switching to or from an MAOI. A direct switch may be an appropriate approach when switching to another agent in the same or similar class (eg, when switching between two SSRIs), when the antidepressant to be discontinued has been used for &lt;1 week, or when the discontinuation is for adverse effects. When choosing the switch strategy, consider the risk of discontinuation symptoms, potential for drug interactions, other antidepressant properties (eg, half-life, adverse effects, and pharmacodynamics), and the degree of symptom control desired (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2018b','lexi-content-ref-23459282','lexi-content-ref-23879318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2018b','lexi-content-ref-23459282','lexi-content-ref-23879318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Switching to or from an MAOI:</i></p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing an MAOI and initiation of sertraline.</p>
<p style="text-indent:-2em;margin-left:6em;">Allow 14 days to elapse between discontinuing sertraline and initiation of an MAOI.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990650"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22012131','lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22012131','lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Not dialyzable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8529300']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8529300'])">Ref</a></span>): No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22012131','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22012131','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22012131','lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22012131','lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987861"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The hepatic dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST, Jeong Park, PharmD, MS, BCTXP, FCCP, FAST, Arun Jesudian, MD, Sasan Sakiani, MD.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Use of sertraline capsules is not recommended in the setting of hepatic impairment as dosage adjustments are not possible with the available strengths (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hepatic impairment prior to treatment initiation:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>Initial or dose titration in patients with preexisting liver cirrhosis: </b></i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Child-Turcotte-Pugh class A and B: Oral: </b>Initial: Administer 50% of the usual recommended indication-specific dose; may increase based on response and tolerability in ≤25 mg increments at ≥2-week intervals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8877033','lexi-content-ref-19530743','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8877033','lexi-content-ref-19530743','lexi-content-ref-Expert.DOH'])">Ref</a></span>). Maximum dose: 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25248846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25248846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Child-Turcotte-Pugh class C: </b>Use is not recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment in patients with chronic, worsening hepatic function during treatment (eg, progression from Child-Turcotte-Pugh class A to B): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Progression from baseline to Child-Turcotte-Pugh class A through B: </b></p>
<p style="text-indent:-2em;margin-left:6em;">For patients currently taking ≤100 mg/day<b>: </b>No dosage adjustment necessary. May increase based on response and tolerability in ≤25 mg increments at ≥2-week intervals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8877033','lexi-content-ref-19530743','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8877033','lexi-content-ref-19530743','lexi-content-ref-Expert.DOH'])">Ref</a></span>). Maximum dose: 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25248846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25248846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">For patients currently taking &gt;100mg/day: Consider a 50% reduction in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25248846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25248846'])">Ref</a></span>). May increase based on response and tolerability in ≤25 mg increments at ≥2-week intervals (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8877033','lexi-content-ref-19530743','lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8877033','lexi-content-ref-19530743','lexi-content-ref-Expert.DOH'])">Ref</a></span>). Maximum dose: 100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25248846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25248846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class C: </b>Use is not recommended due to increased exposure and prolongation of half-life. If continuation of therapy is deemed necessary, consider a 50% reduction in dose with no further dose escalation in collaboration with and close monitoring from provider managing sertraline therapy (eg, psychiatrist) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute worsening hepatic function (eg, requiring hospitalization): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class A and B:</b> Consider a 50% reduction in dose during acute worsening of hepatic function (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>). May resume previous dose if hepatic function returns to pre-event baseline (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>); if hepatic function does not improve to pre-event baseline consider dose reduction to ≤100 mg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25248846']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25248846'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Child-Turcotte-Pugh class C: </b>Use is not recommended due to increased exposure and prolongation of half-life. If continuation of therapy is deemed necessary, consider a 50% reduction in dose with no further dose escalation in collaboration with and close monitoring from provider managing sertraline therapy (eg, psychiatrist) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOH']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOH'])">Ref</a></span>).</p></div>
<div class="block arsc drugH1Div" id="F54357283"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Activation of mania or hypomania</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants (when used as monotherapy) may precipitate a mixed/manic episode in patients with bipolar disorder. Treatment-emergent <b>mania</b> or <b>hypomania</b> in patients with unipolar major depressive disorder (MDD) have been reported, as many cases of bipolar disorder present in episodes of MDD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Non-dose-related; idiosyncratic. Unclear to what extent mood switches represent an uncovering of unrecognized bipolar disorder or a more direct pharmacologic effect independent of diagnosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059','lexi-content-ref-26667012','lexi-content-ref-19958306']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059','lexi-content-ref-26667012','lexi-content-ref-19958306'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; a systematic review observed that the risk of switching increased significantly within the initial 2 years of antidepressant treatment in patients with unipolar MDD receiving an antidepressant as monotherapy, but not thereafter (up to 4.6 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23219059']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23219059'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Family history of bipolar disorder (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depressive episode with psychotic symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Younger age at onset of depression (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15289250','lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15289250','lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Antidepressant resistance (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26667012']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26667012'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Female sex (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32215771','lexi-content-ref-29873955']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32215771','lexi-content-ref-29873955'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Bleeding risk</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs), including sertraline, may increase the risk of bleeding, particularly if used concomitantly with antiplatelets and/or anticoagulants. Multiple observational studies have found an association with SSRI use and a variety of bleeding complications, ranging from bruising, hematomas, petechiae,<b> purpuric disease</b> and <b>epistaxis</b> to stroke, upper GI bleeding,<b> intracranial hemorrhage, </b>postpartum hemorrhage, and perioperative bleeding, although conflicting evidence also exists (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645','lexi-content-ref-29536379','lexi-content-ref-28577352','lexi-content-ref-14581256','lexi-content-ref-18460039','lexi-content-ref-28766108']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645','lexi-content-ref-29536379','lexi-content-ref-28577352','lexi-content-ref-14581256','lexi-content-ref-18460039','lexi-content-ref-28766108'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Possibly via inhibition of serotonin-mediated platelet activation (inhibition of the serotonin reuptake transporter) and subsequent platelet dysfunction. Sertraline is considered to display high affinity for the serotonin reuptake receptor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24314591','lexi-content-ref-18188866']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24314591','lexi-content-ref-18188866'])">Ref</a></span>). SSRIs may also increase gastric acidity, which can increase the risk of GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30081645']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30081645'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Varied; bleeding risk is likely delayed for several weeks until SSRI-induced platelet serotonin depletion becomes clinically significant (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21190637']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21190637'])">Ref</a></span>), although the onset of bleeding may be more unpredictable if patients are taking concomitant antiplatelets, anticoagulants, or nonsteroidal anti-inflammatory agents (NSAIDs). For upper GI bleeding, some studies have found risk to be the highest in the first 28 to 30 days (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19716436','lexi-content-ref-19491861']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19716436','lexi-content-ref-19491861'])">Ref</a></span>), whereas another study reported a median time of onset of 25 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17919277']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17919277'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of anticoagulants and/or antiplatelets (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21948719']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21948719'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Preexisting platelet dysfunction or coagulation disorders (eg, von Willebrand factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27508501','lexi-content-ref-17506225']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27508501','lexi-content-ref-17506225'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of NSAIDs increases the risk for upper GI bleeding (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24777151']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24777151'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fragility fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Limited data from observational studies involving mostly older adults (≥50 years) suggest selective serotonin reuptake inhibitors (SSRIs) are associated with an increased risk of <b>bone fractures</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22638709','lexi-content-ref-17242321','lexi-content-ref-22659406']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22638709','lexi-content-ref-17242321','lexi-content-ref-22659406'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Time-related; mechanism not fully elucidated; postulated to be through a direct effect by SSRIs on bone metabolism via interaction with 5-HT and osteoblast, osteocyte, and/or osteoclast activity (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22659406','lexi-content-ref-30775508']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22659406','lexi-content-ref-30775508'])">Ref</a></span>). An increased tendency for falls may also contribute to the increased risk of fractures associated with SSRIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22638709','lexi-content-ref-18219438']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22638709','lexi-content-ref-18219438'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Delayed; risk appears to increase after initiation and may continue to increase with long-term use. A meta-analysis found risk of fracture increased from 2.9% over 1 year to 5.4% over 2 years; within 5 years, risk increased to 13.4% (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30247774'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Long-term use may be a risk factor (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20703452','lexi-content-ref-30247774']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20703452','lexi-content-ref-30247774'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hyponatremia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors are associated with syndrome of inappropriate antidiuretic hormone secretion (<b>SIADH</b>) and/or <b>hyponatremia </b>(including severe cases), predominantly in the elderly (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25262043','lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25262043','lexi-content-ref-16896026'])">Ref</a></span>). Hyponatremia is reversible with discontinuation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8804257']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8804257'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> May cause SIADH via release of antidiuretic hormone (ADH) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>) or may cause nephrogenic SIADH by increasing the sensitivity of the kidney to ADH (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; usually develops within the first few weeks of treatment (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Older age (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concomitant use of diuretics (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Low body weight (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Lower baseline serum sodium concentration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Volume depletion (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16896026']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16896026'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• History of hyponatremia (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Symptoms of psychosis (potential risk factor) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24094459']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24094459'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Ocular effects</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are associated with <b>acute angle-closure glaucoma</b> (AACG) in case reports and a case-controlled study. AACG may cause symptoms including eye pain, changes in vision, swelling, and redness, which can rapidly lead to permanent blindness if not treated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27993931'])">Ref</a></span>). In addition, SSRIs may be associated with an increased risk of <b>cataract </b>development (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24631758','lexi-content-ref-20207418']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24631758','lexi-content-ref-20207418'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Unclear; hypothesized SSRIs may increase the intraocular pressure via serotonergic effects on ciliary body muscle activation and pupil dilation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27135704','lexi-content-ref-27993931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27135704','lexi-content-ref-27993931'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">For AACG:</p>
<p style="text-indent:-2em;margin-left:8em;">• Females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• ≥50 years of age (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Hyperopia (slight increase) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Personal or family history of AACG (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:8em;">• Inuit or Asian descent (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19587851']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19587851'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Serotonin syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Serotonin syndrome</b> has been reported and typically occurs with coadministration of multiple serotonergic drugs but can occur following a single serotonergic agent at therapeutic doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31837902','lexi-content-ref-31030620']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31837902','lexi-content-ref-31030620'])">Ref</a></span>). The diagnosis of serotonin syndrome is made based on the Hunter Serotonin Toxicity Criteria (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12925718']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12925718'])">Ref</a></span>) and may result in a spectrum of symptoms, such as anxiety, agitation, confusion, delirium, hyperreflexia, muscle rigidity, myoclonus, tachycardia, tachypnea, and tremor. Severe cases may cause hyperthermia, significant autonomic instability (ie, rapid and severe changes in blood pressure and pulse), coma, and seizures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15784664','lexi-content-ref-28148614','lexi-content-ref-18759711']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15784664','lexi-content-ref-28148614','lexi-content-ref-18759711'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Dose-related; overstimulation of serotonin receptors by serotonergic agents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28148614']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28148614'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Rapid; in the majority of cases (74%), onset occurred within 24 hours of treatment initiation, overdose, or change in dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10941349']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10941349'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<i>• </i>Concomitant use of drugs that increase serotonin synthesis, block serotonin reuptake, and/or impair serotonin metabolism (eg, monamine oxidase inhibitors [MAOIs]). Of note, concomitant use of some serotonergic agents, such as MAOIs, are contraindicated.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Sexual dysfunction</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Selective serotonin reuptake inhibitors (SSRIs) are commonly associated with <b>sexual disorders</b> in both men and women. The following adverse reactions have been associated with SSRI use: Ejaculatory delay, <b>orgasm disturbance</b>,<b> erectile dysfunction, decreased libido </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955469','lexi-content-ref-26003261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955469','lexi-content-ref-26003261'])">Ref</a></span>). <b>Priapism </b>and <b>decreased penile sensation</b> have also been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17581442','lexi-content-ref-10665639','lexi-content-ref-29955469','lexi-content-ref-9818637','lexi-content-ref-26003261']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17581442','lexi-content-ref-10665639','lexi-content-ref-29955469','lexi-content-ref-9818637','lexi-content-ref-26003261'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Increases in serotonin may affect other hormones and neurotransmitters involved in sexual function; in particular, testosterone's effect on sexual arousal and dopamine's role in achieving orgasm (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29955469','lexi-content-ref-10333979']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29955469','lexi-content-ref-10333979'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (sexual dysfunction is commonly associated with depression; SSRI-associated sexual dysfunction may be difficult to differentiate in treated patients) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-12243609']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-12243609'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Suicidal thinking and behavior</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Antidepressants are associated with an increased risk of <b>suicidal ideation</b> and <b>suicidal tendencies</b> in pediatric and young adult patients (18 to 24 years of age) in short-term studies. In adults &gt;24 years of age, short-term studies did not show an increased risk of suicidal thinking and behavior, and in older adults (≥65 years of age) a decreased risk was observed. Although data have yielded inconsistent results regarding the association of antidepressants and risk of suicide, particularly among adults, collective evidence shows a trend of an elevated risk of suicidality in younger age groups (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227','lexi-content-ref-12668373','lexi-content-ref-18056231'])">Ref</a></span>). Of note, the risk of a suicide attempt is inherent in major depression and may persist until remission occurs.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Not established; one of several postulated mechanisms is antidepressants may energize suicidal patients to act on impulses; another suggests that antidepressants may produce a worsening of depressive symptoms leading to the emergence of suicidal thoughts and actions (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20553304']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20553304'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset: </i>Varied; increased risk observed in short-term studies (ie, &lt;4 months) in pediatric and young adults; it is unknown whether this risk extends to long-term use (ie, &gt;4 months)</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Children and adolescents (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17485726','lexi-content-ref-16520440','lexi-content-ref-23152227'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Depression (risk of suicide is associated with major depression and may persist until remission occurs)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Withdrawal syndrome</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Withdrawal syndrome</b>, consisting of both somatic symptoms (eg, dizziness, chills, light-headedness, vertigo, electric-shock sensations, paresthesia, fatigue, headache, nausea, tremor, diarrhea, visual disturbances) and psychological symptoms (eg, anxiety, agitation, confusion, insomnia, irritability), has been reported, primarily following abrupt discontinuation. Withdrawal symptoms may also occur following gradual tapering (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25721705']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25721705'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism:</i> Withdrawal; due to reduced availability of serotonin in the CNS with decreasing levels of the selective serotonin reuptake inhibitor (SSRI). Other neurotransmission systems, including increased glutamine and dopamine, may also be affected, as well as the hypothalamic-pituitary-adrenal axis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30501420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset:</i> Intermediate; expected onset is 1 to 10 days (following either abrupt or tapered discontinuation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25721705','lexi-content-ref-30501420']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25721705','lexi-content-ref-30501420'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors:</i></p>
<p style="text-indent:-2em;margin-left:6em;">• Abrupt discontinuation (rather than gradual dosage reduction) of an antidepressant that has lasted &gt;3 weeks, particularly a drug with a half-life &lt;24 hours (eg, paroxetine, venlafaxine) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019','lexi-content-ref-15906018','lexi-content-ref-25677972']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-APA.2010','lexi-content-ref-Hirsch.2019','lexi-content-ref-15906018','lexi-content-ref-25677972'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of antidepressant withdrawal symptoms (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High dose (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Hirsch.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Hirsch.2019'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F220649"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea (20%), nausea (26%), xerostomia (14%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Dizziness (12%), drowsiness (adults: 11%; literature suggests incidence occurs less frequently in children and adolescents compared to adults [Safer 2006]), fatigue (12%), insomnia (20%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Edema (&lt;2%), hypertension (&lt;2%), palpitations (4%), syncope (&lt;2%), tachycardia (&lt;2%), vasodilation (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Alopecia (&lt;2%), bullous dermatitis (&lt;2%), dermatitis (&lt;2%), diaphoresis (&lt;2%), erythematous rash (&lt;2%), follicular rash (&lt;2%), hyperhidrosis (7%), maculopapular rash (&lt;2%), pruritus (&lt;2%), urticaria (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased libido (4% to 7%)<span class="lexi-table-link-container"> (<a aria-label="Decreased Libido table link" class="lexi-table-link" data-table-id="lexi-content-decreased-libido" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-decreased-libido')">table 1</a>)</span><span class="table-link" style="display:none;">Decreased Libido</span>, diabetes mellitus (&lt;2%), galactorrhea not associated with childbirth (&lt;2%), hypercholesterolemia (&lt;2%), hypoglycemia (&lt;2%), hypothyroidism (&lt;2%), weight loss (&gt;7% of body weight; children: 7%; adolescents: 2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Decreased Libido" frame="border" id="lexi-content-decreased-libido" rules="all">
<caption style="text-align:center;">
<b>Sertraline: Adverse Reaction: Decreased Libido</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sertraline)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sertraline)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">7%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mostly 50 mg to 200 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,316</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">973</p></td></tr>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Females</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mostly 50 mg to 200 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,750</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,320</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (≥5%), bruxism (&lt;2%), constipation (6%), decreased appetite (7%), dyspepsia (8%), hematochezia (&lt;2%), increased appetite (&lt;2%), melena (&lt;2%), rectal hemorrhage (&lt;2%), vomiting (adults: 4%; literature suggests incidence is higher in adolescents compared to adults, and is two- to threefold higher in children compared to adults [Safer 2006])</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Ejaculation failure (8%)<span class="lexi-table-link-container"> (<a aria-label="Ejaculation Failure table link" class="lexi-table-link" data-table-id="lexi-content-ejaculation-failure" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ejaculation-failure')">table 2</a>)</span><span class="table-link" style="display:none;">Ejaculation Failure</span>, ejaculatory disorder (3%)<span class="lexi-table-link-container"> (<a aria-label="Ejaculatory Disorder table link" class="lexi-table-link" data-table-id="lexi-content-ejaculatory-disorder" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-ejaculatory-disorder')">table 3</a>)</span><span class="table-link" style="display:none;">Ejaculatory Disorder</span>, erectile dysfunction (4%)<span class="lexi-table-link-container"> (<a aria-label="Erectile Dysfunction table link" class="lexi-table-link" data-table-id="lexi-content-erectile-dysfunction" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-erectile-dysfunction')">table 4</a>)</span><span class="table-link" style="display:none;">Erectile Dysfunction</span>, hematuria (&lt;2%), priapism (&lt;2%), sexual disorder (males: 2%; literature suggests an incidence ranging from 54% to 63% [Higgins 2010; Montejo 2001])<span class="lexi-table-link-container"> (<a aria-label="Sexual Disorder table link" class="lexi-table-link" data-table-id="lexi-content-sexual-disorder" onclick="event.preventDefault(); window.mobileShowLexiTable &amp;&amp; mobileShowLexiTable('lexi-content-sexual-disorder')">table 5</a>)</span><span class="table-link" style="display:none;">Sexual Disorder</span>, urinary incontinence (≥2%), vaginal hemorrhage (&lt;2%)</p>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ejaculation Failure" frame="border" id="lexi-content-ejaculation-failure" rules="all">
<caption style="text-align:center;">
<b>Sertraline: Adverse Reaction: Ejaculation Failure</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sertraline)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sertraline)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">8%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mostly 50 mg to 200 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,316</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">973</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Ejaculatory Disorder" frame="border" id="lexi-content-ejaculatory-disorder" rules="all">
<caption style="text-align:center;">
<b>Sertraline: Adverse Reaction: Ejaculatory Disorder</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sertraline)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sertraline)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">3%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mostly 50 mg to 200 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,316</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">973</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Erectile Dysfunction" frame="border" id="lexi-content-erectile-dysfunction" rules="all">
<caption style="text-align:center;">
<b>Sertraline: Adverse Reaction: Erectile Dysfunction</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sertraline)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sertraline)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">4%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mostly 50 mg to 200 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,316</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">973</p></td></tr></tbody></table>
<table border="1" class="lexi-modal-content" data-hyperlink="yes" data-table-id="Sexual Disorder" frame="border" id="lexi-content-sexual-disorder" rules="all">
<caption style="text-align:center;">
<b>Sertraline: Adverse Reaction: Sexual Disorder</b></caption>
<colgroup><col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
<col align="left"/>
</colgroup><thead>
<tr>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Drug (Sertraline)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Placebo </b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Population</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Dose</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Indication</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Sertraline)</b></p></th>
<th align="left">
<p style="text-indent:0em;text-align:left;">
<b>Number of Patients (Placebo)</b></p></th></tr></thead>
<tbody>
<tr>
<td align="left">
<p style="text-indent:0em;text-align:left;">2%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">0%</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Males</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Mostly 50 mg to 200 mg per day</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">Major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, social anxiety disorder, and premenstrual dysphoric disorder</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">1,316</p></td>
<td align="left">
<p style="text-indent:0em;text-align:left;">973</p></td></tr></tbody></table>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Hemorrhage (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased liver enzymes (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylaxis (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal gait (&lt;2%), agitation (8%), anxiety (children and adolescents: ≥2%), ataxia (&lt;2%), coma (&lt;2%), confusion (&lt;2%), euphoria (&lt;2%), hallucination (&lt;2%), hypertonia (&lt;2%), hypoesthesia (&lt;2%), impaired consciousness (&lt;2%), irritability (&lt;2%), lethargy (&lt;2%), malaise (≥5%), psychomotor agitation (&lt;2%), seizure (&lt;2%), tremor (9%), yawning (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Hyperkinetic muscle activity (children and adolescents: ≥2%), muscle spasm (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision (&lt;2%), mydriasis (&lt;2%), visual disturbance (4%)</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm (&lt;2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Aggressive behavior</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia, muscle twitching</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Epistaxis</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial arrhythmia, atrioventricular block, bradycardia, prolonged QT interval on ECG (Beach 2014; Funk 2013), torsades de pointes (Danielsson 2016), vasculitis, ventricular tachycardia (Patel 2013)</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Erythema multiforme (Khan 2012), skin photosensitivity, Stevens-Johnson syndrome (Jan 1999), toxic epidermal necrolysis</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Gynecomastia (Kaufman 2013), hyperglycemia (Khoza 2011), hyperprolactinemia, hyponatremia (literature suggests incidence of hyponatremia among SSRIs ranging from &lt;1% to as high as 32%) (Jacob 2006; Varela Piñón 2017), menstrual disease, secondary amenorrhea (Ekinci 2019), SIADH (Jacob 2006), weight gain (slight increase, primarily in adults with long-term therapy) (Fava 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Burning sensation of mouth (Purohith 2022), oromandibular dystonia (Doruk 2021), pancreatitis (Malbergier 2004)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Abnormal orgasm (Jing 2016), decreased penile sensation (Bolton 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Trescoli-Serrano 1996), aplastic anemia, coagulation time increased (altered platelet function) (Apseloff 1997), Henoch-Schönlein purpura (Fatima 2022), immune thrombocytopenia (Krivy 1995), leukopenia, neutropenia (Ozcanli 2005), pancytopenia, purpuric disease (periorbital) (Kayhan 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatic failure, hepatitis (Persky 2003), hepatotoxicity (Persky 2003), jaundice (Verrico 2000)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Angioedema (Gales 1994), hypersensitivity reaction (Dadic-Hero 2011), serum sickness</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Akathisia (Madhusoodanan 2010), anosmia (including hyposmia), electric shock-like sensation (Viani 2022), hyperactive behavior (including restlessness occurring in children at a two- to threefold higher incidence compared to adolescents [Safer 2006]), hypomania (Kumar 2000), intracranial hemorrhage (Douros 2018), mania (Ghaziuddin 1994), myoclonus (hypnic jerks) (Kumar 2023), neuroleptic malignant syndrome (Stevens 2008), nightmares, psychosis (Popli 1997), reversible cerebral vasoconstriction syndrome (Bain 2013), serotonin syndrome (Duignan 2019), suicidal ideation (children and adolescents) (Hammad 2006), suicidal tendencies (children and adolescents) (Hammad 2006), trismus (Holmberg 2018), withdrawal syndrome (Fava 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Bone fracture (Rabenda 2013), dystonia (Madhusoodanan 2010), lupus-like syndrome (Hussain 2008), rhabdomyolysis (Gareri 2009)</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Acute angle-closure glaucoma (Kirkham 2017), blindness, cataract (Erie 2014), maculopathy (Dang 2016), oculogyric crisis, optic nerve damage (with papilledema) (Abuallut 2023), optic neuritis</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute kidney injury</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Eosinophilic pneumonitis, hypersensitivity pneumonitis (Virdee 2019), pulmonary hypertension</p></div>
<div class="block coi drugH1Div" id="F220665"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Use of monoamine oxidase inhibitors (MAOIs) including methylene blue (concurrently or within 14 days of stopping an MAOI or sertraline); concurrent use with pimozide; hypersensitivity (eg, anaphylaxis, angioedema) to sertraline or any component of the formulation; concurrent use with disulfiram (oral solution only).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although sertraline is contraindicated per the manufacturer labeling when used in combination with linezolid, new evidence suggests that the combination is unlikely to cause serotonin syndrome (0.06% to 3% risk), and therefore these agents can be administered concomitantly when necessary. Monitor patients on this combination; average duration of serotonin toxicity is ~4 days; however, risks may be greater with longer durations of concurrent therapy. Educate patients on the signs and symptoms of serotonin syndrome (Bai 2022; Butterfield 2012; Karkow 2017; Kufel 2023; Narita 2007; Taylor 2006).</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block war drugH1Div" id="F220646"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CNS depression: Has a low potential to impair cognitive or motor performance; caution operating hazardous machinery or driving.</p>
<p style="text-indent:-2em;margin-left:4em;">• QT prolongation: QTc prolongation and torsades de pointes have been reported with sertraline use. Most reports involved other risk factors; use with caution in patients with risk factors for QTc prolongation. Studies have shown correlations with serum sertraline concentrations.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with hepatic impairment; clearance is decreased and half-life and plasma concentrations are increased; dose reduction may be necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">• Seizure disorder: Use with caution in patients with a previous seizure disorder or condition predisposing to seizures such as brain damage or alcoholism.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: Monitor growth in pediatric patients. Given their lower body weight, lower doses are advisable in pediatric patients in order to avoid excessive plasma levels, despite slightly greater metabolism efficiency than adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Latex sensitivity: Use oral solution formulation with caution in patients with latex sensitivity; dropper dispenser contains dry, natural rubber.</p>
<p style="text-indent:-2em;margin-left:4em;">• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:4em;">• Tartrazine: Capsules contain tartrazine (FD&amp;C Yellow No. 5), which may cause allergic-type reactions (including bronchial asthma) in susceptible individuals, particularly those who also have aspirin sensitivity.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878628"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Selective serotonin reuptake inhibitor (SSRI)-associated behavioral activation (ie, restlessness, hyperkinesis, hyperactivity, agitation) is two- to threefold more prevalent in children compared to adolescents; it is more prevalent in adolescents compared to adults. Somnolence (including sedation and drowsiness) is more common in adults compared to children and adolescents and SSRI-associated vomiting is two- to threefold more prevalent in children compared to adolescents; it is more prevalent in adolescents compared to adults (Safer 2006).</p></div>
<div class="block foc drugH1Div" id="F220658"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral, as hydrochloride: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 150 mg, 200 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Concentrate, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zoloft: 20 mg/mL (60 mL) [contains alcohol, usp, menthol]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg/mL (60 mL)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zoloft: 25 mg [scored; contains fd&amp;c blue #1 (brill blue) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, polysorbate 80, quinoline (d&amp;c yellow #10) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zoloft: 50 mg [scored; contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zoloft: 100 mg [scored; contains polysorbate 80]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p></div>
<div class="block geq drugH1Div" id="F220642"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F220668"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsules</b> (Sertraline HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">150 mg (per each): $6.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">200 mg (per each): $6.17</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (Sertraline HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $0.68 - $1.13</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Concentrate</b> (Zoloft Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg/mL (per mL): $5.68</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Sertraline HCl Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $0.05 - $2.87</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.03 - $2.85</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.04 - $2.85</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Zoloft Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">25 mg (per each): $16.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $16.53</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $16.53</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F57397474"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zoloft: 25 mg, 50 mg [contains corn starch, fd&amp;c yellow #6 (sunset yellow), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Zoloft: 100 mg [contains corn starch, fd&amp;c red #40 (allura red ac dye), quinoline yellow (d&amp;c yellow #10)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 25 mg, 50 mg, 100 mg</p></div>
<div class="block admp drugH1Div" id="F52613849"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: May be administered without regard to food; administer once daily dosage either in morning or evening.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: Swallow whole; do not open, crush, or chew.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral concentrate: Must dilute oral concentrate before use; see "Preparation for Administration: Pediatric." Direct administration of the pure solution is astringent and may numb the tongue/mouth for at least a day, even if the mouth is rinsed extensively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pfizer.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pfizer.2016'])">Ref</a></span>).</p></div>
<div class="block adm drugH1Div" id="F220662"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Oral:</b></p>
<p style="text-indent:-2em;margin-left:4em;">Capsules: Swallow capsules whole; do not open, chew, or crush.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral solution: Must be diluted immediately before use to make the preparation more palatable. Direct administration of the pure solution is astringent and may numb the tongue/mouth for at least a day, even if the mouth is rinsed extensively (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Pfizer.2016']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Pfizer.2016'])">Ref</a></span>). <b>Note:</b> Use with caution in patients with latex sensitivity; dropper dispenser contains dry natural rubber.</p></div>
<div class="block sts drugH1Div" id="F220678"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:0em;display:inline">Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p></div>
<div class="block meg drugH1Div" id="F7874831"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and at <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F019839s108%2C20990s062lbl.pdf%23page%3D37&amp;token=YV6lC86tv22A27SpGbMTiC9Xsr%2FxfGuVmYK8ZdwpgspvDDYAmyV1SzXePzEeerxzYOSSPBU0qiFBLo%2FmWbSvQLHD15nM1CUP8rZas9HqSRNm11Oqc4fgUgbFKIDldzws&amp;TOPIC_ID=12787" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/019839s108,20990s062lbl.pdf#page=37</a>, must be dispensed with this medication.</p></div>
<div class="block usep drugH1Div" id="F53568825"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Treatment of obsessive-compulsive disorder (FDA approved in ages ≥6 years and adults); treatment of major depressive disorder, panic disorder (with or without agoraphobia), posttraumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder (social phobia) (FDA approved in adults).</p></div>
<div class="block mst drugH1Div" id="F220738"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Sertraline may be confused with cetirizine, selegiline, Serevent, Soriatane</p>
<p style="text-indent:-2em;margin-left:4em;">Zoloft may be confused with Zocor</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Beers Criteria: Selective Serotonin Reuptake Inhibitors (SSRIs) are identified in the Beers Criteria as potentially inappropriate medications to be used with caution in patients 65 years and older due to the potential to cause or exacerbate syndrome of inappropriate antidiuretic hormone secretion (SIADH) or hyponatremia; monitor sodium concentration closely when initiating or adjusting the dose in older adults (Beers Criteria [AGS 2023]).</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F220720"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2B6 (minor), CYP2C19 (minor), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (major); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2D6 (weak)</p></div>
<div class="block dri drugH1Div" id="F220651"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Abrocitinib: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Abrocitinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Antiplatelet Properties (e.g., P2Y12 inhibitors, NSAIDs, SSRIs, etc.): May enhance the antiplatelet effect of other Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Selective Serotonin Reuptake Inhibitors may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk of psychomotor impairment may be enhanced. Management: Patients receiving selective serotonin reuptake inhibitors should be advised to avoid alcohol.  Monitor for increased psychomotor impairment in patients who consume alcohol during treatment with selective serotonin reuptake inhibitors.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Almotriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamines: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability). Initiate amphetamines at lower doses, monitor frequently, and adjust doses as needed.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anagrelide: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Anticoagulants: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Anticoagulants. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiemetics (5HT3 Antagonists): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antiplatelet Agents (P2Y12 Inhibitors): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Antiplatelet Agents (P2Y12 Inhibitors). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antipsychotic Agents: Serotonergic Agents (High Risk) may enhance the adverse/toxic effect of Antipsychotic Agents. Specifically, serotonergic agents may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotic Agents may enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Apixaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Apixaban. Specifically, the risk for bleeding may be increased.  Management: Carefully consider risks and benefits of this combination and monitor closely.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aspirin: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Aspirin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bemiparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Bemiparin.  Management: Avoid concomitant use of bemiparin with antiplatelet agents. If concomitant use is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Brexanolone: Selective Serotonin Reuptake Inhibitors may enhance the CNS depressant effect of Brexanolone. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bromopride: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">BuPROPion: May enhance the adverse/toxic effect of Sertraline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">BusPIRone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Caplacizumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Caplacizumab. Specifically, the risk of bleeding may be increased.  Management: Avoid coadministration of caplacizumab with antiplatelets if possible. If coadministration is required, monitor closely for signs and symptoms of bleeding. Interrupt use of caplacizumab if clinically significant bleeding occurs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Sertraline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cephalothin: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Cephalothin. Specifically, the risk for bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors. Citalopram may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Collagenase (Systemic): Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Collagenase (Systemic). Specifically, the risk of injection site bruising and or bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyclobenzaprine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Moderate): May decrease the serum concentration of Sertraline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP3A4 Inducers (Strong): May decrease the serum concentration of Sertraline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cyproheptadine: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dabigatran Etexilate: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Dabigatran Etexilate. Agents with Antiplatelet Properties may increase the serum concentration of Dabigatran Etexilate. This mechanism applies specifically to clopidogrel.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dapoxetine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Do not use serotonergic agents (high risk) with dapoxetine or within 7 days of serotonergic agent discontinuation. Do not use dapoxetine within 14 days of monoamine oxidase inhibitor use. Dapoxetine labeling lists this combination as contraindicated.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May decrease the serum concentration of Sertraline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: May enhance the anticoagulant effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Deoxycholic Acid: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Deoxycholic Acid. Specifically, the risk for bleeding or bruising in the treatment area may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Desmopressin: Hyponatremia-Associated Agents may enhance the hyponatremic effect of Desmopressin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexmethylphenidate-Methylphenidate: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextromethorphan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipyrone: May decrease the serum concentration of Sertraline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Disulfiram: May enhance the adverse/toxic effect of Products Containing Ethanol. Management: Do not use disulfiram with dosage forms that contain ethanol.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">DULoxetine: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of DULoxetine. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of DULoxetine. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Edoxaban: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Edoxaban. Specifically, the risk of bleeding may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Eletriptan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxaparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Enoxaparin.  Management: Discontinue antiplatelet agents prior to initiating enoxaparin whenever possible. If concomitant administration is unavoidable, monitor closely for signs and symptoms of bleeding.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ergot Derivatives: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erythromycin (Systemic): May enhance the adverse/toxic effect of Sertraline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fenfluramine: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: Sertraline may increase the serum concentration of Fosphenytoin-Phenytoin. Fosphenytoin-Phenytoin may decrease the serum concentration of Sertraline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gepirone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gilteritinib: May diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. Management: Avoid use of this combination if possible. If the combination cannot be avoided, monitor closely for evidence of reduced response to the selective serotonin reuptake inhibitor.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Grapefruit Juice: May increase the serum concentration of Sertraline.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Haloperidol: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Haloperidol. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Heparin: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Heparin.  Management: Decrease the dose of heparin or agents with antiplatelet properties if coadministration is required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Anticoagulant/Antiplatelet Effects (eg, Alfalfa, Anise, Bilberry): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Bleeding may occur.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibritumomab Tiuxetan: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Ibritumomab Tiuxetan. Both agents may contribute to impaired platelet function and an increased risk of bleeding. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ibrutinib: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Icosapent Ethyl: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Inotersen: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ioflupane I 123: Selective Serotonin Reuptake Inhibitors may diminish the diagnostic effect of Ioflupane I 123. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lasmiditan: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lecanemab: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of hemorrhage may be increased.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of Levoketoconazole.  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levomethadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Limaprost: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Linezolid: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lipid Emulsion (Fish Oil Based): May enhance the adverse/toxic effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lorcaserin (Withdrawn From US Market): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metaxalone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methadone: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrimeprazine: Products Containing Ethanol may enhance the adverse/toxic effect of Methotrimeprazine. Specifically, a disulfiram-like reaction may occur and CNS depressant effects may be increased.  Management: Avoid products containing alcohol in patients treated with methotrimeprazine.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methylene Blue: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Methylene Blue. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metoclopramide: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Consider monitoring for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mivacurium: Selective Serotonin Reuptake Inhibitors may increase the serum concentration of Mivacurium. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors (Antidepressant): Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Monoamine Oxidase Inhibitors (Antidepressant). This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Fluoride (with ADE): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with AE, No Iron): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nefazodone: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective). Nonsteroidal Anti-Inflammatory Agents (COX-2 Selective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Nonselective): Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Nonsteroidal Anti-Inflammatory Agents (Nonselective). Nonsteroidal Anti-Inflammatory Agents (Nonselective) may diminish the therapeutic effect of Selective Serotonin Reuptake Inhibitors.  Management: Consider alternatives to NSAIDs. Monitor for evidence of bleeding and diminished antidepressant effects. It is unclear whether COX-2-selective NSAIDs reduce risk.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nonsteroidal Anti-Inflammatory Agents (Topical): May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Obinutuzumab: Agents with Antiplatelet Properties may enhance the adverse/toxic effect of Obinutuzumab. Specifically, the risk of serious bleeding-related events may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Omega-3 Fatty Acids: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ondansetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4 and CYP2D6): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Opioid Agonists (metabolized by CYP3A4): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ornidazole: May enhance the adverse/toxic effect of Products Containing Ethanol. Specifically, a disulfiram-like reaction may occur.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Oxitriptan: Serotonergic Agents (High Risk) may enhance the serotonergic effect of Oxitriptan. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ozanimod: May enhance the adverse/toxic effect of Serotonergic Agents (High Risk).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentosan Polysulfate Sodium: May enhance the adverse/toxic effect of Agents with Antiplatelet Properties. Specifically, the risk of bleeding may be increased by concurrent use of these agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pentoxifylline: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pimozide: Selective Serotonin Reuptake Inhibitors may enhance the adverse/toxic effect of Pimozide. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pirtobrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prostacyclin Analogues: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">QT-prolonging Agents (Highest Risk): QT-prolonging Agents (Indeterminate Risk - Avoid) may enhance the QTc-prolonging effect of QT-prolonging Agents (Highest Risk).  Management: Monitor for QTc interval prolongation and ventricular arrhythmias when these agents are combined. Patients with additional risk factors for QTc prolongation may be at even higher risk.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ramosetron: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rasagiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Rasagiline. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rivaroxaban: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Rivaroxaban.  Management: Carefully consider risks and benefits of this combination and monitor closely; Canadian labeling recommends avoiding prasugrel or ticagrelor.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Safinamide: May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Use the lowest effective dose of SSRIs in patients treated with safinamide and monitor for signs and symptoms of serotonin syndrome/serotonin toxicity.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secnidazole: Products Containing Ethanol may enhance the adverse/toxic effect of Secnidazole. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the antiplatelet effect of other Selective Serotonin Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of other Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selegiline: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Selegiline. This could result in serotonin syndrome. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selumetinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Agents (High Risk, Miscellaneous): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Non-Opioid CNS Depressants: Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonergic Non-Opioid CNS Depressants. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonergic Opioids (High Risk): May enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin 5-HT1D Receptor Agonists (Triptans): May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Serotonin/Norepinephrine Reuptake Inhibitors: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Serotonin/Norepinephrine Reuptake Inhibitors. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Serotonin/Norepinephrine Reuptake Inhibitors. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. St John's Wort may decrease the serum concentration of Serotonergic Agents (High Risk). Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Succinylcholine: Sertraline may increase the serum concentration of Succinylcholine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Syrian Rue: May enhance the serotonergic effect of Serotonergic Agents (High Risk). This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: Selective Serotonin Reuptake Inhibitors may enhance the hyponatremic effect of Thiazide and Thiazide-Like Diuretics. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thioridazine: CYP2D6 Inhibitors (Weak) may increase the serum concentration of Thioridazine.  Management: Consider avoiding concomitant use of thioridazine and weak CYP2D6 inhibitors. If combined, monitor closely for QTc interval prolongation and arrhythmias. Some weak CYP2D6 inhibitors list use with thioridazine as a contraindication.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thrombolytic Agents: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Thrombolytic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thyroid Products: Selective Serotonin Reuptake Inhibitors may diminish the therapeutic effect of Thyroid Products. Thyroid product dose requirements may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">TraMADol: May enhance the adverse/toxic effect of Selective Serotonin Reuptake Inhibitors. Specifically, the risk for serotonin syndrome/serotonin toxicity and seizures may be increased. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and seizures when these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tricyclic Antidepressants: Sertraline may enhance the serotonergic effect of Tricyclic Antidepressants. Sertraline may increase the serum concentration of Tricyclic Antidepressants.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, autonomic instability, mental status changes) and increased TCA concentrations/effects if these agents are combined.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Urokinase: Agents with Antiplatelet Properties may enhance the anticoagulant effect of Urokinase. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vasopressin: Drugs Suspected of Causing SIADH may enhance the therapeutic effect of Vasopressin. Specifically, the pressor and antidiuretic effects of vasopressin may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Venlafaxine: Selective Serotonin Reuptake Inhibitors may enhance the antiplatelet effect of Venlafaxine. Selective Serotonin Reuptake Inhibitors may enhance the serotonergic effect of Venlafaxine. This could result in serotonin syndrome.  Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin E (Systemic): May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Selective Serotonin Reuptake Inhibitors may enhance the anticoagulant effect of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vortioxetine: May enhance the antiplatelet effect of Selective Serotonin Reuptake Inhibitors. Vortioxetine may enhance the serotonergic effect of Selective Serotonin Reuptake Inhibitors. This could result in serotonin syndrome. Management: Monitor for signs and symptoms of serotonin syndrome/serotonin toxicity (eg, hyperreflexia, clonus, hyperthermia, diaphoresis, tremor, mental status changes) when these agents are combined. In addition, monitor for signs and symptoms of bleeding.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zanubrutinib: May enhance the antiplatelet effect of Agents with Antiplatelet Properties.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Zolpidem: Sertraline may increase the serum concentration of Zolpidem. <i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F55501556"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Sertraline is approved for the treatment of unipolar major depressive disorder. If treatment for major depressive disorder is initiated for the first time in patients planning to become pregnant, sertraline is one of the preferred selective serotonin reuptake inhibitors (SSRIs) (Larsen 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Sertraline is also approved for the treatment of premenstrual dysphoric disorder. For patients attempting to conceive, symptom-onset dosing may be beneficial to minimize potential fetal exposure (Ismaili 2016; Lanza di Scalea 2019).</p>
<p style="text-indent:0em;margin-top:2em;">SSRIs may be associated with male and female treatment-emergent sexual dysfunction (Coskuner 2018; WFSBP [Bauer 2013]). Decreased libido has been reported in females and males; ejaculation failure, ejaculation dysfunction, and ejaculation disorders have been reported in males with sertraline use. This may also be a manifestation of the psychiatric disorder. The actual risk associated with sertraline is not known. SSRI-related sexual dysfunction may resolve with dose reduction or discontinuation of the SSRI; in some cases, sexual dysfunction may persist once therapy is discontinued (Coskuner 2018; Jing 2016; Waldinger 2015).</p>
<p style="text-indent:0em;margin-top:2em;">Sertraline is used off label for the treatment of premature ejaculation. Although data are limited, some studies have shown SSRIs may impair the motility of spermatozoa; therefore, use of other treatments may be preferred in patients planning to father a child (Althof 2014; Siroosbakht 2019; Sylvester 2019).</p></div>
<div class="block pri drugH1Div" id="F220669"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Sertraline crosses the human placenta. Cord blood and amniotic fluid concentrations are less than those in the maternal serum; concentrations in the amniotic fluid correlate with maternal dose (Newport 2003; Paulzen 2017).</p>
<p style="text-indent:0em;margin-top:2em;">As a class, selective serotonin reuptake inhibitors (SSRIs) have been evaluated extensively in pregnant patients. Studies focusing on newborn outcomes following first trimester exposure often have inconsistent results due to differences in study design and confounders such as maternal disease and social factors (Anderson 2020; Biffi 2020; Fitton 2020; Reefhuis 2015; Womersley 2017). Adverse effects in the newborn following SSRI exposure late in the third trimester can include apnea, constant crying, cyanosis, feeding difficulty, hyperreflexia, hypo- or hypertonia, hypoglycemia, irritability, jitteriness, respiratory distress, seizures, temperature instability, tremor, and vomiting. Prolonged hospitalization, respiratory support, or tube feedings may be required. Symptoms may be due to the toxicity of the SSRIs or a discontinuation syndrome and may be consistent with serotonin syndrome associated with SSRI treatment. Persistent pulmonary hypertension of the newborn has been reported with SSRI exposure; although the absolute risk is small, monitoring of infants exposed to SSRIs late in pregnancy is recommended (Masarwa 2019; Ng 2019). The long-term effects of in utero SSRI exposure on infant neurodevelopment and behavior are not known (CANMAT [MacQueen 2016]).</p>
<p style="text-indent:0em;margin-top:2em;">Due to pregnancy-induced physiologic changes some pharmacokinetic parameters of sertraline may be altered. Serum concentrations may be decreased in the third trimester; however, due to the wide therapeutic reference range, dose adjustments may not be needed. Close clinical monitoring as pregnancy progresses and therapeutic drug monitoring to detect patterns of changing plasma concentrations is recommended to assist dose-adjustment when needed (Schoretsanitis 2020).</p>
<p style="text-indent:0em;margin-top:2em;">If treatment for major depressive disorder is initiated for the first time during pregnancy, sertraline is one of the preferred SSRIs (CANMAT [MacQueen 2016]; Larsen 2015; WFSBP [Bauer 2013]). Untreated or inadequately treated psychiatric illness may lead to poor adherence with prenatal care and adverse pregnancy outcomes. Therapy with antidepressants during pregnancy should be individualized; treatment with antidepressant medication is recommended for pregnant patients with severe major depressive disorder (ACOG 2008; CANMAT [MacQueen 2016]). Patients treated for major depression and who are euthymic prior to pregnancy are more likely to experience a relapse when medication is discontinued (68%) as compared to pregnant patients who continue taking antidepressant medications (26%) (Cohen 2006).</p>
<p style="text-indent:0em;margin-top:2em;">Data collection to monitor pregnancy and infant outcomes following exposure to antidepressant medications is ongoing. Patients exposed to antidepressants during pregnancy are encouraged to enroll in the National Pregnancy Registry for Antidepressants. Pregnant patients 18 to 45 years of age or their health care providers may contact the registry to enroll; enrollment should be done as early in pregnancy as possible (1-866-961-2388 or https://womensmentalhealth.org/research/pregnancyregistry/antidepressants/).</p></div>
<div class="block mopp drugH1Div" id="F53568824"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Weight, height, BMI (longitudinal monitoring); closely monitor patients for depression, clinical worsening, suicidality, psychosis, or unusual changes in behavior (eg, anxiety, agitation, panic attacks, insomnia, irritability, hostility, impulsivity, akathisia, hypomania, mania, social functioning), particularly during the initial 1 to 2 months of therapy or during periods of dosage adjustments (increases or decreases); signs/symptoms of serotonin syndrome such as mental status changes (eg, agitation, hallucinations, delirium, coma), autonomic instability (eg, tachycardia, labile BP, diaphoresis), neuromuscular changes (eg, tremor, rigidity, myoclonus), GI symptoms (eg, nausea, vomiting, diarrhea), and/or seizures; serum sodium in at-risk populations.</p></div>
<div class="block pha drugH1Div" id="F220645"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Antidepressant with selective inhibitory effects on presynaptic serotonin (5-HT) reuptake and only very weak effects on norepinephrine and dopamine neuronal uptake. In vitro studies demonstrate no significant affinity for adrenergic, cholinergic, GABA, dopaminergic, histaminergic, serotonergic, or benzodiazepine receptors.</p></div>
<div class="block phk drugH1Div" id="F220664"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action:</p>
<p style="text-indent:-2em;margin-left:4em;">Anxiety disorders (generalized anxiety, obsessive-compulsive, panic, and posttraumatic stress disorder): Initial effects may be observed within 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Issari 2016; Varigonda 2016; WFSBP [Bandelow 2023a]); some experts suggest up to 12 weeks of treatment may be necessary for response, particularly in patients with obsessive-compulsive disorder and posttraumatic stress disorder (BAP [Baldwin 2014]; Katzman 2014; WFSBP [Bandelow 2023a]; WFSBP [Bandelow 2023b]).</p>
<p style="text-indent:-2em;margin-left:4em;">Body dysmorphic disorder: Initial effects may be observed within 2 weeks; some experts suggest up to 12 to 16 weeks of treatment may be necessary for response in some patients (Phillips 2008).</p>
<p style="text-indent:-2em;margin-left:4em;">Depression: Initial effects may be observed within 1 to 2 weeks of treatment, with continued improvements through 4 to 6 weeks (Papakostas 2006; Posternak 2005; Szegedi 2009; Taylor 2006).</p>
<p style="text-indent:-2em;margin-left:4em;">Premenstrual dysphoric disorder: Initial effects may be observed within the first few days of treatment, with response at the first menstrual cycle of treatment (ISPMD [Nevatte 2013]).</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: 98%.</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic; may involve CYP2B6, CYP2C9, CYP2C19, CYP2D6, and CYP3A4 (Chen 2020; Markowitz 2000; Rajasingham 2018); extensive first pass metabolism; forms metabolite N-desmethylsertraline (APA [Gelenberg 2010]); <b>Note: </b>Children 6 to 17 years may metabolize sertraline slightly better than adults, as pediatric AUCs and peak concentrations were 22% lower than adults when adjusted for weight; however, lower doses are recommended for younger pediatric patients to avoid excessive drug levels).</p>
<p style="text-indent:-2em;margin-left:2em;">Bioavailability: Bioavailability of tablets and solution are equivalent.</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: Sertraline: Mean: 26 hours; N-desmethylsertraline (not as active as parent drug): 62 to 104 hours.</p>
<p style="text-indent:-2em;margin-left:4em;">Children 6 to 12 years: Mean: 26.2 hours (Alderman 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Children 13 to 17 years: Mean: 27.8 hours (Alderman 1998).</p>
<p style="text-indent:-2em;margin-left:4em;">Adults 18 to 45 years: Mean: 27.2 hours (Alderman 1998).</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: Sertraline: 4.5 to 8.4 hours.</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (40% to 45% as metabolites); feces (40% to 45%; 12% to 14% as unchanged drug).</p></div>
<div class="block phksp drugH1Div" id="F51159888"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: Sertraline clearance was reduced in patients with chronic mild liver impairment resulting in a 3-fold greater exposure. Sertraline C<sub>max</sub>, AUC and half-life were 1.7-fold, 4-fold, and 2.5-fold higher following a single dose of sertraline in patients with stable chronic cirrhosis (Démolis 1996).</p>
<p style="text-indent:-2em;margin-left:2em;">Pediatric: Children 6 to 17 years may metabolize sertraline slightly better than adults, as pediatric AUCs and peak concentrations were 22% lower than adults when adjusted for weight; however, lower doses are recommended for younger pediatric patients to avoid excessive drug levels)</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: Plasma clearance 40% lower; steady state achieved after 2 to 3 weeks</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F2869406"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Solotik | Zoloft</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Anilar | Apo sertralina | Asertral | Atenix | Bicromil | Celonfex | Cratular | Dimena | Erta | Insertec | Irradial | Psicotil | Serlina | Sertralina hlb | Sertralina lepret | Sertralina rospaw | Sertralina teva | Sertranova | Servantax Vannier | Stralina | Vunot | Zoloft</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Adjuvin | Gladem | Sertralin | Sertralin accord | Sertralin Actavis | Sertralin bluefish | Sertralin G L | Sertralin genericon | Sertralin krka | Sertralin Pfizer | Sertralin ranbaxy | Sertralin ratiopharm | Sertralin Regiomedica | Sertralin sandoz | Sertralin viatris | Tresleen</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo sertraline | Apotex sertraline | Auro Sertraline | Chemmart sertraline | Concorz | Detralon | Eleva | Genrx Sertraline | Ipca sertraline | Noumed sertraline | Pharmacor Sertraline | Pip sertraline | Ppa sertraline | Selasmin | Sertra | Sertracor | Sertraline actavis | Sertraline an | Sertraline Drla | Sertraline Generic Health | Sertraline lapl | Sertraline pfizer | Sertraline Sandoz | Sertraline str | Sertraline watson | Sertraline Winthrop | Sertraline wt | Sertraline-dp | Sertraline-GA | Sertratrust | Setrona | Terry white chemists sertraline | Xydep | Zoloft | Zoltra</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Atralin | Chear | Mudiral | Repose | Sartra | Sb serta | Serlin | Serolux | Sertal | Setra | Syche | Tralin | Zosert</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Serlain | Sertraline ab | Sertraline apotex | Sertraline eg | Sertraline ratiopharma | Sertraline teva</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Asentra | Misol | Sertraline accord | Sertran | Stimuloton | Zoloft</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Assert | Cefelic | Cloridrato de sertralina | Dieloft | Novativ | Recapser | Sercerin | Sered | Serenata | Serolift | Seronip | Sertralin | Sertralina | Tolrest | Trasolin | Trelim | Zoloft | Zysertin</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Gladem | Seralin Mepha | Sertragen | Sertral Spirig | Sertralin 1 A Pharma | Sertralin Actavis | Sertralin Adico | Sertralin Helvepharm | Sertralin mepha | Sertralin Pfizer | Sertralin sandoz | Sertralin Spirig | Zoloft | Zoloft P</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Sertraline pfizer | Zoloft</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Altruline | Deprax | Dieloft | Eleval | Emergen | Implicane | Iseren | Sedoran | Serivo | Seronex | Sertac | Sertralina</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">BEI YU | Jin de si | Kuai wu you | Le yuan | Wei ta ting | Xi tong jing | Yu lang | Yu luo xin | Zoloft</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Aurasert | Desfatigan | Dominium | Inosert | Lesefer | Pandomil | Relmar | Serlane | Sertralina | Sertranex | Sertranquil | Setrax | Sosser | Zolof</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Adjuvin | Apo sertral | Asentra | Serlift | Sertivan | Sertralin | Sertralin apotex | Sertralin aurovitas | Sertralin Generico | Sertralin krka | Sertralin mylan | Sertralin Orion | Sertralin ratiopharm | Sertralin sandoz | Sertralin teva | Sertralin Vipharm | Sertraline accord | Setaloft | Stimuloton | Zoloft</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Besitran | Gladem | Sertra | Sertralin 1 A Pharma | Sertralin Actavis | Sertralin AL | Sertralin Aristo | Sertralin Aurobindo | Sertralin AWD | Sertralin Basics | Sertralin beta | Sertralin bluefish | Sertralin CT | Sertralin Esparma | Sertralin Heumann | Sertralin hexal | Sertralin Hormosan | Sertralin Lindopharm | Sertralin Real | Sertralin sandoz | Sertralin Siga | Sertralin Stada | Sertralin tad | Sertralin Winthrop | Sertralon | Zoloft</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Sertralin | Sertralin 1a farma | Sertralin hexal</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Alisten | Altruline | Aprexia | Emergen | Implicane | Insertec | Prodepres | Serlift | Serta | Sertra | Sertralina | Sertralina Calox | Sertralive | Sinalgina | Solutrex | Zoxx</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Conexine | Deprax | Eleval | Serivo | Serolux | Sertex | Sertralina | Sosser | Suxlim | Zoloft | Zosert</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Asentra | Erset | Serlift | Sertral | Sertralin | Sertralin genericon | Sertralin nycomed | Sertraline accord | Sertraline Lannacher | Sertraline teva | Zoloft</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Agrelocit | Depr stat | Deprestat | Lustral | Moodapex | Opiraline | Serlift | Seronorm | Serpass | Sertral | Sertraline | Seserine | Sirto</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Altisben | Aremis | Aserin | Besitran | Semonic | Sertralina accord | Sertralina Almus | Sertralina alter | Sertralina aphar | Sertralina apotex | Sertralina aurobindo | Sertralina aurovitas | Sertralina bayvit | Sertralina Bexal | Sertralina Cinfa | Sertralina combino | Sertralina cuve | Sertralina davur | Sertralina edigen | Sertralina grapa | Sertralina juventus | Sertralina kern | Sertralina Lareq | Sertralina Mabo | Sertralina merck | Sertralina mundogen | Sertralina normon | Sertralina pensa | Sertralina pharma combix | Sertralina pharmacia | Sertralina Pharmagenus | Sertralina Qualigen | Sertralina ratiopharm | Sertralina rimafar | Sertralina rubio | Sertralina sandoz | Sertralina stada | Sertralina tarbis | Sertralina tecnigen | Sertralina teva | Sertralina Vir | Sertralina vir pharma | Sertralina winthrop</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Sertraline</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Sertralin Actavis | Sertralin Alternova | Sertralin hexal | Sertralin krka | Sertralin Orion | Sertralin Pfizer | Sertralin ranbaxy | Sertralin ratiopharm | Sertralin teva | Sertraline accord | Zoloft</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Sertraline actavis | Sertraline Almus | Sertraline als | Sertraline Alter | Sertraline Arrow | Sertraline biogaran | Sertraline Cristers | Sertraline eg | Sertraline evolugen | Sertraline G Gam | Sertraline Isomed | Sertraline mylan | Sertraline pfizer | Sertraline qualimed | Sertraline Ranbaxy | Sertraline ratiopharm | Sertraline Sandoz | Sertraline Winthrop | Sertraline Zydus | Zoloft</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Lustral | Sertraline | Sertraline HCL</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Epilyd | Neurosedine | Serolux | Serotyp | Sertral | Sertraline/actavis | Sertraline/Generics | Sertraline/mylan | Sertraline/ranbaxy | Zoloft | Zolotrin | Zortal</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Apo sertraline | Aurasert | Hc sertraline | Pms Sertraline | Serdep | Sertima | Setaloft | Setrof | Zoloft</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Asentra | Halea | Sertralin Genera | Sonalia | Tralin | Zoloft</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Asentra | Camidlin | Gerotralin | Serlift | Serlosane | Sertadepi | Sertralin hexal | Sertralin ratiopharm | Sertraline Aurobindo | Setaloft | Stimuloton | Zoloft</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Anexin | Antipres | Deptral | Fatral | Fridep | Iglodep | Nudep | Serlof | Sernade | Sertraline | Zerlin | Zoloft</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Bellsert | Depreger | Lusert | Lustral | Seretral | Serimel | Serlan | Serlo | Sertraline | Sertraline actavis | Sertraline bluefish | Sertraline Krka | Sertraniche | Zoloft</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Lustral | Serenada</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Asert | Cnsert | Daxid | Depsar | Depsert | Eccite | Episod | Inosert | Lindep | Lupisert | Normaset | Osmoset | Psyline | Resert | Retalin | Rollosert | Sedeptine | Senbest | Senta | Sentral | Septaline | Serbest | Serdep | Serenata | Serin 50 | Serjet | Serlift | Serlin | Sermind | Serne | Sernext | Seronorm | Serotra | Serta | Sertacad | Sertagress | Sertaj | Sertapik | Sertawin | Sertee | Serteo | Sertil | Sertima | Sertin | Sertranat | Sertrax | Setalin | Setral | Snatos | Srt | Stalin | Tralin | Xsert | Zert-od | Zosert | Zotral</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Dosertra | Sertralina | Sertralina accord | Sertralina Actavis | Sertralina angenerico | Sertralina Arrow | Sertralina aurobindo | Sertralina Doc | Sertralina eg | Sertralina Fg | Sertralina krka | Sertralina merck | Sertralina pensa | Sertralina pfizer | Sertralina ranbaxy | Sertralina ratiopharm | Sertralina sandoz | Sertralina tad pharma | Sertralina tecnigen | Sertralina Teva Pharma B.V. | Tatig | Tralforin | Zoloft</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Seralin | Setral | Solotik | Zoloft</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Jzoloft | Sertraline</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Inosert | Serlin | Sertima | Zoloft | Zosert</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Pharma sertraline | Sandoz sertraline | Seltra | Sertraline | Sertram | Sultran | Traline | Yungjin sertraline | Zoloft</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Zoloft</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Deprine | Pms Sertraline | Restraline | Selectra | Sertine | Sertra | Zoloft</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Asentra | Serlift | Sertral | Sertralin nycomed | Sertralin Orion | Sertraline accord | Sertraline auro | Sertraline Lannacher | Sertraline teva | Stimuloton | Zoloft</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Docsertraline | Serlain | Sertralin hexal | Sertralin ratiopharm | Sertraline apotex | Sertraline eg</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Asentra | Serlift | Sertralin accord | Sertralin Generico | Sertraline Lannacher | Sertraline teva | Stimuloton | Zoloft</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Deprestat | Inidep | Lustral | No Dep | Psytral | Sertam | Sertraline gt | Zoloft</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acortral | Aleval | Alpraser Simple | Altruline | Aluprex | Ansdepcan | Biotrade | Deptral | Elemax | Equivac | Evomere | Implicane | Preducine | Prorecap | Prosertin | Resteral | Salinaker | Serenata | Serlift | Serolux | Sertex | Sertralina | Sindetev | Trakos | Tressvin | Vedavixa | Vultrig | Zajartral | Zoloft</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Asentra | Aurasert | Serenata | Serlift | Sertima | Setrof | Sisalon | Zoloft</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Besitran | Sertralin Stada | Sertraline | Sertraline A | Sertraline accord | Sertraline alpharma | Sertraline BModesto | Sertraline cf | Sertraline eg | Sertraline Merck | Sertraline pch | Sertraline Sandoz | Zoloft</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Sertralin | Sertralin bluefish | Sertralin hexal | Sertralin teva | Sertraline accord | Zoloft</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Arrow sertraline | Noumed sertraline | Setrona | Zoloft</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Ariale | Deprax | Dominium | Eleval | Emergen | Serlift | Serlin | Serloft | Sertima | Sertirine | Sertline | Sertralina | Sertralina Marfan | Sertraline | Sertrexa | Zephyr | Zoloft</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Deperin | Exulten | Inosert | Serenata | Sertragen | Setrof | Startline | Zolodin | Zoloft | Zolotral | Zolpro | Zosert | Zotral</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Awa rest | Aytimax | Biosert | Cetralex | Demstrin | Depralin | Deprinil | Equasert | Euloft | Fedsert | Foldtralin | Freedep | Graset | Hysern | Kasertine | Lintex | Lintre | Medserline | Miloft | Pertral | Preloft | Reline | Rozanto | Sabert | Sayloft | Senereta | Seon | Seralin | Serlin | Serloft | Serlox | Seroft | Serog | Sert | Sertex | Sertima | Sertral | Serwan | Setalin | Skud | Snapta | Traline | Treloft | Valuser | Xastrin | Xofit | Yesme | Zaline | Zatraline | Zergex | Zertralin | Zertralin plus | Zoloft | Zota | Zotral</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Aposerta | Asentra | Asertin | Luxeta | Miravil | Sastium | Sertralina krka | Sertraline Aurobindo | Sertraline aurovitas | Sertraline bluefish | Sertranorm | Setaloft | Stimuloton | Zoloft</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Sertraline | Sertraline HCL | Zoloft</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Aserta | Semonic | Serlin | Sertralina | Sertralina aurobindo | Sertralina Bluefish | Sertralina krka | Sertralina mylan | Sertralina Parke-Davis | Sertralina stada | Zoloft</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Deprax | Dipresol | Doxime | Eleval | Emergen | Insertec | Modutrol | Psicomed | Sertralix | Sertrina | Verax</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Setral | Zoloft</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Adjuvin | Als sertralina | Asentra | Sertralina aurobindo | Zoloft</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Aleval | Asentra | Deprefolt | Seralin | Serenata | Serlift | Stimuloton | Torin | Zoloft</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Apo sertraline | Lustral | Setral | Solotik</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Oralin | Sertralin 2care4 | Sertralin Actavis | Sertralin bluefish | Sertralin ebb | Sertralin hexal | Sertralin ivax | Sertralin krka | Sertralin ranbaxy | Sertralin ratiopharm | Sertralin sandoz | Sertralin teva | Sertralin zentiva | Sertraline accord | Sertramyl | Sertrone | Setaloft | Setralin sandoz | Zoloft</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Apo sertraline | Inosert | Setrof | Zoloft</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Asentra | Mapron | Sertiva | Sertralin Arrow | Sertralin teva | Zoloft</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Asentra | Serlift | Sertiva | Sertralin | Sertralin Orion | Sertralin teva | Sertraline accord | Sertramerck | Stimuloton | Zoloft</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Selrotine | Serlin | Sertra | Sertraline | Sertraline pfizer | Sertraline Sandoz | Sisalon | Starin | Zoloft | Zotaline</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Netral | Sertraline actavis | Sertraline zentiva | Serval | Solotik | Zolit | Zoloft</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Lustec | Lustral | Misol | Selectra | Seralin | Serdep | Serotop | Serteva | Zeleft</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Cenzoft | Kinloft | Purtraline | Serlin | Seruline | You Jet | Zapline | Zoloft</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Adjuvin | Asentra | Depralin | Emoton | Serlift | Sertraloft | Sertralux | Stimuloton | Zaloks | Zoloft</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Dominium | Emergen | Nirvan | Senpur | Sertralina | Sertralina sandoz | Sertralina Szabo | Sertralix | Sertrina | Sertrol | Trialine | Zoloft</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Biosertral | Chear | Conexine | Lomaz | Lusedan | Satil | Sered | Serline | Serolux | Seron | Sertralina | Sertralina clorhidrato | Sertranquil | Tialin | Zoloft</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Clealine</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Adco zertra | Arrow sertraline | Austell Sertraline | Dyna sertraline | Serdep | Serlife | Sertra | Sertzol | Zolid | Zoloft | Zylin</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Serenata</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37139272">
<a name="37139272"></a>Abuallut I, Alqassim AY, Ayyashi R. Sertraline-induced optic nerve dysfunction. <i>Cureus</i>. 2023;15(3):e36976. doi:10.7759/cureus.36976<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/37139272/pubmed" id="37139272" target="_blank">37139272</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21961502">
<a name="21961502"></a>Aigner M, Treasure J, Kaye W, Kasper S; WFSBP Task Force on Eating Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of eating disorders. <i>World J Biol Psychiatry</i>. 2011;12(6):400-443. doi:10.3109/15622975.2011.602720<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/21961502/pubmed" id="21961502" target="_blank">21961502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3960626">
<a name="3960626"></a>Alade SL, Brown RE, Paquet A Jr. Polysorbate 80 and E-Ferol toxicity. <i>Pediatrics</i>. 1986;77(4):593-597.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/3960626/pubmed" id="3960626" target="_blank">3960626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9549959">
<a name="9549959"></a>Alderman J, Wolkow R, Chung M, et al. Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy. <i>J Am Acad Child Adolesc Psychiatry</i>. 1998;37(4):386-394.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/9549959/pubmed" id="9549959" target="_blank">9549959</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25356302">
<a name="25356302"></a>Althof SE, McMahon CG, Waldinger MD, et al. An update of the International Society of Sexual Medicine's guidelines for the diagnosis and treatment of premature ejaculation (PE). <i>Sex Med</i>. 2014;2(2):60-90. doi:10.1002/sm2.28<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/25356302/pubmed" id="25356302" target="_blank">25356302</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22176943">
<a name="22176943"></a>American Academy of Child and Adolescent Psychiatry (AACAP). Practice parameter for the assessment and treatment of children and adolescents with obsessive-compulsive disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2012;51(1):98-113. doi:10.1016/j.jaac.2011.09.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/22176943/pubmed" id="22176943" target="_blank">22176943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18378767">
<a name="18378767"></a>American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin: Clinical Management Guidelines for Obstetricians-Gynecologists No. 92 April 2008 (Replaces Practice Bulletin Number 87, November 2007). Use of Psychiatric Medications During Pregnancy and Lactation. <i>Obstet Gynecol.</i> 2008;111(4):1001-1020.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/18378767/pubmed" id="18378767" target="_blank">18378767</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2010">
<a name="APA.2010"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf. Published October 2010. Accessed April 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.2018">
<a name="APA.2018"></a>American Psychiatric Association (APA). Practice guideline for the treatment of patients with panic disorder. 2nd edition.  http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/panicdisorder.pdf. Published January 2009. Accessed May 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-APA.1">
<a name="APA.1"></a>American Psychological Association (APA). Clinical practice guideline for the treatment of depression across three age cohorts. https://www.apa.org/depression-guideline/guideline.pdf. Published February 16, 2019. Accessed April 21, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32777011">
<a name="32777011"></a>Anderson KN, Lind JN, Simeone RM, et al. Maternal use of specific antidepressant medications during early pregnancy and the risk of selected birth defects. <i>JAMA Psychiatry</i>. 2020;77(12):1246-1255. doi:10.1001/jamapsychiatry.2020.2453<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/32777011/pubmed" id="32777011" target="_blank">32777011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21190637">
<a name="21190637"></a>Andrade C, Sandarsh S, Chethan KB, Nagesh KS. Serotonin reuptake inhibitor antidepressants and abnormal bleeding: a review for clinicians and a reconsideration of mechanisms. <i>J Clin Psychiatry</i>. 2010;71(12):1565‐1575. doi:10.4088/JCP.09r05786blu<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/21190637/pubmed" id="21190637" target="_blank">21190637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24777151">
<a name="24777151"></a>Anglin R, Yuan Y, Moayyedi P, Tse F, Armstrong D, Leontiadis GI. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. <i>Am J Gastroenterol</i>. 2014;109(6):811‐819. doi:10.1038/ajg.2014.82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/24777151/pubmed" id="24777151" target="_blank">24777151</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9068934">
<a name="9068934"></a>Apseloff G, Wilner KD, Gerber N, Tremaine LM. Effect of sertraline on protein binding of warfarin. <i>Clin Pharmacokinet</i>. 1997;32(suppl 1):37‐42. doi:10.2165/00003088-199700321-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/9068934/pubmed" id="9068934" target="_blank">9068934</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16554853">
<a name="16554853"></a>Arafa M, Shamloul R. Efficacy of sertraline hydrochloride in treatment of premature ejaculation: a placebo-controlled study using a validated questionnaire. <i>Int J Impot Res</i>. 2006;18(6):534-538. doi:10.1038/sj.ijir.3901469<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16554853/pubmed" id="16554853" target="_blank">16554853</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36534400">
<a name="36534400"></a>Bai AD, McKenna S, Wise H, Loeb M, Gill SS. Association of linezolid with risk of serotonin syndrome in patients receiving antidepressants.<i> JAMA Netw Open</i>. 2022;5(12):e2247426. doi:10.1001/jamanetworkopen.2022.47426<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/36534400/pubmed" id="36534400" target="_blank">36534400</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23859861">
<a name="23859861"></a>Bain J, Segal D, Amin R, Monoky D, Thompson SJ. Call-Fleming syndrome: headache in a 16-year-old girl. <i>Pediatr Neurol</i>. 2013;49(2):130‐133.e1. doi:10.1016/j.pediatrneurol.2013.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/23859861/pubmed" id="23859861" target="_blank">23859861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28778697">
<a name="28778697"></a>Bala A, Nguyen HMT, Hellstrom WJG. Post-SSRI sexual dysfunction: a literature review. <i>Sex Med Rev</i>. 2018;6(1):29‐34. doi:10.1016/j.sxmr.2017.07.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28778697/pubmed" id="28778697" target="_blank">28778697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23219059">
<a name="23219059"></a>Baldessarini RJ, Faedda GL, Offidani E, et al. Antidepressant-associated mood-switching and transition from unipolar major depression to bipolar disorder: a review. <i>J Affect Disord</i>. 2013;148(1):129‐135. doi:10.1016/j.jad.2012.10.033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/23219059/pubmed" id="23219059" target="_blank">23219059</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24713617">
<a name="24713617"></a>Baldwin DS, Anderson IM, Nutt DJ, et al. Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British Association for Psychopharmacology. <i>J Psychopharmacol</i>. 2014;28(5):403-439. doi:10.1177/0269881114525674<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/24713617/pubmed" id="24713617" target="_blank">24713617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15669894">
<a name="15669894"></a>Ball SG, Kuhn A, Wall D, Shekhar A, Goddard AW. Selective serotonin reuptake inhibitor treatment for generalized anxiety disorder: a double-blind, prospective comparison between paroxetine and sertraline. <i>J Clin Psychiatry</i>. 2005;66(1):94-99.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15669894/pubmed" id="15669894" target="_blank">15669894</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900161">
<a name="35900161"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part I: anxiety disorders. <i>World J Biol Psychiatry</i>. 2023a;24(2):79-117. doi:10.1080/15622975.2022.2086295<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/35900161/pubmed" id="35900161" target="_blank">35900161</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35900217">
<a name="35900217"></a>Bandelow B, Allgulander C, Baldwin DS, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders - version 3. Part II: OCD and PTSD. <i>World J Biol Psychiatry</i>. 2023b;24(2):118-134. doi:10.1080/15622975.2022.2086296<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/35900217/pubmed" id="35900217" target="_blank">35900217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28148614">
<a name="28148614"></a>Bartlett D. Drug-Induced Serotonin Syndrome. <i>Crit Care Nurse</i>. 2017;37(1):49‐54. doi:10.4037/ccn2017169<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28148614/pubmed" id="28148614" target="_blank">28148614</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23879318">
<a name="23879318"></a>Bauer M, Pfennig A, Severus E, Whybrow PC, Angst J, Möller HJ; World Federation of Societies of Biological Psychiatry Task Force on Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders. <i>World J Biol Psychiatry</i>. 2013;14(5):334-385.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/23879318/pubmed" id="23879318" target="_blank">23879318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25677972">
<a name="25677972"></a>Bauer M, Severus E, Köhler S, Whybrow PC, Angst J, Möller HJ; WFSBP Task Force on Treatment Guidelines for Unipolar Depressive Disorders. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. Part 2: maintenance treatment of major depressive disorder-update 2015. <i>World J Biol Psychiatry</i>. 2015;16(2):76-95. doi:10.3109/15622975.2014.1001786<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/25677972/pubmed" id="25677972" target="_blank">25677972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12479080">
<a name="12479080"></a>Bauer M, Whybrow PC, Anst J, et al. World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 2: Maintenance treatment of major depressive disorder and treatment of chronic depressive disorders and subthreshold depressions. <i>World J Biol Psychiatry</i>. 2002;3(2):69-86.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/12479080/pubmed" id="12479080" target="_blank">12479080</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24922496">
<a name="24922496"></a>Beach SR, Kostis WJ, Celano CM, et al. Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation. <i>J Clin Psychiatry</i>. 2014;75(5):e441‐e449. doi:10.4088/JCP.13r08672<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/24922496/pubmed" id="24922496" target="_blank">24922496</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22299006">
<a name="22299006"></a>Berle JO, Spigset O. Antidepressant use during breastfeeding. <i>Curr Womens Health Rev</i>. 2011;7(1):28-34.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/22299006/pubmed" id="22299006" target="_blank">22299006</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32135392">
<a name="32135392"></a>Biffi A, Cantarutti A, Rea F, Locatelli A, Zanini R, Corrao G. Use of antidepressants during pregnancy and neonatal outcomes: an umbrella review of meta-analyses of observational studies. <i>J Psychiatr Res</i>. 2020;124:99-108. doi:10.1016/j.jpsychires.2020.02.023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/32135392/pubmed" id="32135392" target="_blank">32135392</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30081645">
<a name="30081645"></a>Bixby AL, VandenBerg A, Bostwick JR. Clinical management of bleeding risk with antidepressants. <i>Ann Pharmacother</i>. 2019;53(2):186‐194. doi:10.1177/1060028018794005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/30081645/pubmed" id="30081645" target="_blank">30081645</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28888714">
<a name="28888714"></a>Bobo WV. The diagnosis and management of bipolar I and II disorders: clinical practice update. <i>Mayo Clin Proc</i>. 2017;92(10):1532‐1551. doi:10.1016/j.mayocp.2017.06.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28888714/pubmed" id="28888714" target="_blank">28888714</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16709553">
<a name="16709553"></a>Bolton JM, Sareen J, Reiss JP. Genital anaesthesia persisting six years after sertraline discontinuation. <i>J Sex Marital Ther</i>. 2006;32(4):327‐330. doi:10.1080/00926230600666410<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16709553/pubmed" id="16709553" target="_blank">16709553</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17581442">
<a name="17581442"></a>Bonnot O, Warot D, Cohen D. Priapism associated with sertraline. <i>J Am Acad Child Adolesc Psychiatry</i>. 2007;46(7):790‐791. doi:10.1097/chi.0b013e318067da56<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/17581442/pubmed" id="17581442" target="_blank">17581442</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15784664">
<a name="15784664"></a>Boyer EW, Shannon M. The serotonin syndrome. <i>N Engl J Med</i>. 2005;352(11):1112-1120. doi:10.1056/NEJMra041867<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15784664/pubmed" id="15784664" target="_blank">15784664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16848646">
<a name="16848646"></a>Brawman-Mintzer O, Knapp RG, Rynn M, Carter RE, Rickels K. Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. <i>J Clin Psychiatry</i>. 2006;67(6):874-881.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16848646/pubmed" id="16848646" target="_blank">16848646</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30526179">
<a name="30526179"></a>Bruun SB, Petersen I, Kristensen NR, Cronin-Fenton D, Pedersen AB. Selective serotonin reuptake inhibitor use in hip fracture patients: a Danish nationwide prevalence study. <i>Acta Orthop</i>. 2019;90(1):33‐39. doi:10.1080/17453674.2018.1543842<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/30526179/pubmed" id="30526179" target="_blank">30526179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22139199">
<a name="22139199"></a>Butterfield JM, Lawrence KR, Reisman A, Huang DB, Thompson CA, Lodise TP. Comparison of serotonin toxicity with concomitant use of either linezolid or comparators and serotonergic agents: an analysis of phase III and IV randomized clinical trial data. <i>J Antimicrob Chemother.</i> 2012;67(2):494-502. doi:10.1093/jac/dkr467<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/22139199/pubmed" id="22139199" target="_blank">22139199</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27508501">
<a name="27508501"></a>Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature. <i>Psychother Psychosom</i>. 2016;85(5):270‐288. doi:10.1159/000447034<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/27508501/pubmed" id="27508501" target="_blank">27508501</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Casper.2020">
<a name="Casper.2020"></a>Casper RF, Yonkers KA. Treatment of premenstrual syndrome and premenstrual dysphoric disorder. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 13, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6423951">
<a name="6423951"></a>Centers for Disease Control (CDC). Unusual syndrome with fatalities among premature infants: association with a new intravenous vitamin E product. <i>MMWR Morb Mortal Wkly Rep</i>. 1984;33(14):198-199. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00000319.htm</a>.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/6423951/pubmed" id="6423951" target="_blank">6423951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20703452">
<a name="20703452"></a>Ceylan ME, Maner F. Long-term use of fluoxetine and multiple skeleton fractures. <i>Eur J Clin Pharmacol</i>. 2010;66(12):1279. doi:10.1007/s00228-010-0880-8<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/20703452/pubmed" id="20703452" target="_blank">20703452</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16467545">
<a name="16467545"></a>Chambers CD, Hernandez-Diaz S, Van Marter LJ, et al. Selective Serotonin-Reuptake Inhibitors and Risk of Persistent Pulmonary Hypertension of the Newborn. <i>N Engl J Med.</i> 2006;354(6):579-587.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16467545 /pubmed" id="16467545 " target="_blank">16467545 </a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28994901">
<a name="28994901"></a>Chan CH, Huang HH, Lin CH, Kuan YC, Loh EW, Lan TH. Risk of first onset stroke in SSRI-exposed adult subjects: survival analysis and examination of age and time effects. <i>J Clin Psychiatry</i>. 2017;78(8):e1006‐e1012. doi:10.4088/JCP.16m11123<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28994901/pubmed" id="28994901" target="_blank">28994901</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27135704">
<a name="27135704"></a>Chen HY, Lin CL, Lai SW, Kao CH. Association of selective serotonin reuptake inhibitor use and acute angle-closure glaucoma. <i>J Clin Psychiatry</i>. 2016;77(6):e692‐e696. doi:10.4088/JCP.15m10038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/27135704/pubmed" id="27135704" target="_blank">27135704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32372212">
<a name="32372212"></a>Chen S, Wu Q, Li X, et al. The role of hepatic cytochrome P450s in the cytotoxicity of sertraline. <i>Arch Toxicol</i>. 2020;94(7):2401-2411. doi:10.1007/s00204-020-02753-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/32372212/pubmed" id="32372212" target="_blank">32372212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29483201">
<a name="29483201"></a>Cheung AH, Zuckerbrot RA, Jensen PS, Laraque D, Stein REK; GLAD-PC Steering Group. Guidelines for Adolescent Depression in Primary Care (GLAD-PC): Part II. Treatment and ongoing management. <i>Pediatrics</i>. 2018;141(3):e20174082. doi:10.1542/peds.2017-4082<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/29483201/pubmed" id="29483201" target="_blank">29483201</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16449615">
<a name="16449615"></a>Cohen LS, Altshuler LL, Harlow BL, et al. Relapse of major depression during pregnancy in women who maintain or discontinue antidepressant treatment. <i>JAMA</i>. 2006;295(5):499-507. doi:10.1001/jama.295.5.499<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16449615/pubmed" id="16449615" target="_blank">16449615</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29463440">
<a name="29463440"></a>Coskuner ER, Culha MG, Ozkan B, Kaleagasi EO. Post-SSRI sexual dysfunction: preclinical to clinical. Is it fact or fiction? <i>Sex Med Rev</i>. 2018;6(2):217-223. doi:10.1016/j.sxmr.2017.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/29463440/pubmed" id="29463440" target="_blank">29463440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19587851">
<a name="19587851"></a>Costagliola C, Parmeggiani F, Semeraro F, Sebastiani A. Selective serotonin reuptake inhibitors: a review of its effects on intraocular pressure. <i>Curr Neuropharmacol</i>. 2008;6(4):293‐310. doi:10.2174/157015908787386104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/19587851/pubmed" id="19587851" target="_blank">19587851</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Craske.1">
<a name="Craske.1"></a>Craske M. Generalized anxiety disorder in adults: management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 20, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crone.2023">
<a name="Crone.2023"></a>Crone C, Fochtmann LJ, Attia E, et al; Guideline Writing Group<i>. The American Psychiatric Association Practice Guideline for the Treatment of Patients With Eating Disorders</i>. 4th ed. American Psychiatric Association; 2023. doi:10.1176/appi.books.9780890424865</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crow.2019">
<a name="Crow.2019"></a>Crow SJ. Bulimia nervosa in adults: Pharmacotherapy. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 23, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16636635">
<a name="16636635"></a>Csoka AB, Shipko S. Persistent sexual side effects after SSRI discontinuation. <i>Psychother Psychosom</i>. 2006;75(3):187-188. doi:10.1159/000091777<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16636635/pubmed" id="16636635" target="_blank">16636635</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21448115">
<a name="21448115"></a>Dadić-Hero E, Ružić K, Grahovac T, Graovac M, Palijan TZ, Sepić-Grahovac D. Allergic reactions—outcome of sertraline and escitalopram treatments. <i>Psychiatr Danub</i>. 2011;23(1):120‐122.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/21448115/pubmed" id="21448115" target="_blank">21448115</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15877709">
<a name="15877709"></a>Dahl AA, Ravindran A, Allgulander C, Kutcher SP, Austin C, Burt T. Sertraline in generalized anxiety disorder: efficacy in treating the psychic and somatic anxiety factors. <i>Acta Psychiatr Scand</i>. 2005;111(6):429-435.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15877709/pubmed" id="15877709" target="_blank">15877709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19716436">
<a name="19716436"></a>Dall M, Schaffalitzky de Muckadell OB, Lassen AT, Hansen JM, Hallas J. An association between selective serotonin reuptake inhibitor use and serious upper gastrointestinal bleeding. <i>Clin Gastroenterol Hepatol</i>. 2009;7(12):1314‐1321. doi:10.1016/j.cgh.2009.08.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/19716436/pubmed" id="19716436" target="_blank">19716436</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28924409">
<a name="28924409"></a>Dang S, Shah CP. The best of the best: a review of select retina case reports published in 2015. <i>Digit J Ophthalmol</i>. 2016;22(4):79‐81. doi:10.5693/djo.01.2016.06.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28924409/pubmed" id="28924409" target="_blank">28924409</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26574175">
<a name="26574175"></a>Danielsson B, Collin J, Jonasdottir Bergman G, Borg N, Salmi P, Fastbom J. Antidepressants and antipsychotics classified with torsades de pointes arrhythmia risk and mortality in older adults - a Swedish nationwide study. <i>Br J Clin Pharmacol</i>. 2016;81(4):773‐783. doi:10.1111/bcp.12829<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/26574175/pubmed" id="26574175" target="_blank">26574175</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25262043">
<a name="25262043"></a>De Picker L, Van Den Eede F, Dumont G, Moorkens G, Sabbe BG. Antidepressants and the risk of hyponatremia: a class-by-class review of literature. <i>Psychosomatics</i>. 2014;55(6):536‐547. doi:10.1016/j.psym.2014.01.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/25262043/pubmed" id="25262043" target="_blank">25262043</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10665639">
<a name="10665639"></a>Deisenhammer EA, Trawöger R. Penile anesthesia associated with sertraline use. <i>J Clin Psychiatry</i>. 1999;60(12):869-870. doi:10.4088/jcp.v60n1218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/10665639/pubmed" id="10665639" target="_blank">10665639</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8877033">
<a name="8877033"></a>Démolis JL, Angebaud P, Grangé JD, Coates P, Funck-Brentano C, Jaillon P. Influence of liver cirrhosis on sertraline pharmacokinetics. <i>Br J Clin Pharmacol</i>. 1996;42(3):394-397. doi:10.1046/j.1365-2125.1996.42817.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/8877033/pubmed" id="8877033" target="_blank">8877033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31577402">
<a name="31577402"></a>
<i>Depression in children and young people: identification and management</i>. London: National Institute for Health and Care Excellence (NICE) (UK); June 25, 2019.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/31577402/pubmed" id="31577402" target="_blank">31577402</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Diler.2002">
<a name="Diler.2002"></a>Diler R, Avci A. Selective Serotonin Reuptake Inhibitor Discontinuation Syndrome in Children: Six Case Reports. <i>Current Therapeutic Research.</i> 2002;63(3):188-197.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16434782">
<a name="16434782"></a>Dopheide JA. Recognizing and treating depression in children and adolescents. <i>Am J Health Syst Pharm</i>. 2006;63(3):233-243.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16434782/pubmed" id="16434782" target="_blank">16434782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34185745">
<a name="34185745"></a>Doruk N, Dogrul BN. Sertraline induced oromandibular dystonia and galactorrhea: a case report. <i>Psychiatr Danub</i>. 2021;33(2):191-192. doi:10.24869/psyd.2021.191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/34185745/pubmed" id="34185745" target="_blank">34185745</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29536379">
<a name="29536379"></a>Douros A, Ades M, Renoux C. Risk of intracranial hemorrhage associated with the use of antidepressants inhibiting serotonin reuptake: a systematic review. <i>CNS Drugs</i>. 2018;32(4):321‐334. doi:10.1007/s40263-018-0507-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/29536379/pubmed" id="29536379" target="_blank">29536379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31837902">
<a name="31837902"></a>Duignan KM, Quinn AM, Matson AM. Serotonin syndrome from sertraline monotherapy: a case report. <i>Am J Emerg Med</i>. 2019;158487. doi:10.1016/j.ajem.2019.158487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/31837902/pubmed" id="31837902" target="_blank">31837902</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12925718">
<a name="12925718"></a>Dunkley EJ, Isbister GK, Sibbritt D, Dawson AH, Whyte IM. The Hunter Serotonin Toxicity Criteria: simple and accurate diagnostic decision rules for serotonin toxicity. <i>QJM</i>. 2003;96(9):635-642. doi:10.1093/qjmed/hcg109<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/12925718/pubmed" id="12925718" target="_blank">12925718</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30865005">
<a name="30865005"></a>Ekinci N, Güneş S, Kalinli M, Ekinci Ö. Sertraline-related amenorrhea in an adolescent. <i>Clin Neuropharmacol</i>. 2019;42(3):99‐100. doi:10.1097/WNF.0000000000000336<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/30865005/pubmed" id="30865005" target="_blank">30865005</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24631758">
<a name="24631758"></a>Erie JC, Brue SM, Chamberlain AM, Hodge DO. Selective serotonin reuptake inhibitor use and increased risk of cataract surgery: a population-based, case-control study. <i>Am J Ophthalmol</i>. 2014;158(1):192‐197.e1. doi:10.1016/j.ajo.2014.03.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/24631758/pubmed" id="24631758" target="_blank">24631758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20207418">
<a name="20207418"></a>Etminan M, Mikelberg FS, Brophy JM. Selective serotonin reuptake inhibitors and the risk of cataracts: a nested case-control study. <i>Ophthalmology</i>. 2010;117(6):1251‐1255. doi:10.1016/j.ophtha.2009.11.042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/20207418/pubmed" id="20207418" target="_blank">20207418</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOH">
<a name="Expert.DOH"></a>Expert opinion. Senior Hepatic Editorial Team: Matt Harris, PharmD, MHS, BCPS, FAST; Jeong Park, PharmD, MS, BCTXP, FCCP, FAST; Arun Jesudian, MD; Sasan Sakiani, MD.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8573661">
<a name="8573661"></a>Fabre LF, Abuzzahab FS, Amin M, et al. Sertraline Safety and Efficacy in Major Depression: A Double-Blind Fixed-Dose Comparison With Placebo. <i>Biol Psychiatry.</i> 1995;38(9):592-602.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/8573661/pubmed" id="8573661" target="_blank">8573661</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35482936">
<a name="35482936"></a>Fatima R, Acharya A, Bozorgnia F, Garg A, Altorok N. Sertraline-associated immunoglobulin A vasculitis. <i>Am J Ther</i>. 2022;29(4):484-486. doi:10.1097/MJT.0000000000001516<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/35482936/pubmed" id="35482936" target="_blank">35482936</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25721705">
<a name="25721705"></a>Fava GA, Gatti A, Belaise C, Guidi J, Offidani E. Withdrawal symptoms after selective serotonin reuptake inhibitor discontinuation: a systematic review. <i>Psychother Psychosom</i>. 2015;84(2):72‐81. doi:10.1159/000370338<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/25721705/pubmed" id="25721705" target="_blank">25721705</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19621834">
<a name="19621834"></a>Fenske JN, Schwenk TL. Obsessive compulsive disorder: diagnosis and management. <i>Am Fam Physician</i>. 2009;80(3):239-245.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/19621834/pubmed" id="19621834" target="_blank">19621834</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10937449">
<a name="10937449"></a>Findling RL, Reed MD, Blumer JL. Pharmacological Treatment of Depression in Children and Adolescents. <i>Paediatr Drugs.</i> 1999;1(3):161-182.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/10937449/pubmed" id="10937449" target="_blank">10937449</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31648376">
<a name="31648376"></a>Fitton CA, Steiner MFC, Aucott L, et al. In utero exposure to antidepressant medication and neonatal and child outcomes: a systematic review. <i>Acta Psychiatr Scand</i>. 2020;141(1):21-33. doi:10.1111/acps.13120<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/31648376/pubmed" id="31648376" target="_blank">31648376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17485726">
<a name="17485726"></a>Friedman RA, Leon AC. Expanding the black box - depression, antidepressants, and the risk of suicide. <i>N Engl J Med</i>. 2007;356(23):2343‐2346. doi:10.1056/NEJMp078015<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/17485726/pubmed" id="17485726" target="_blank">17485726</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24259697">
<a name="24259697"></a>Funk KA, Bostwick JR. A comparison of the risk of QT prolongation among SSRIs. <i>Ann Pharmacother</i>. 2013;47(10):1330‐1341. doi:10.1177/1060028013501994<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/24259697/pubmed" id="24259697" target="_blank">24259697</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28554948">
<a name="28554948"></a>Gabriel M, Sharma V. Antidepressant discontinuation syndrome. <i>CMAJ</i>. 2017;189(21):E747. doi:10.1503/cmaj.160991<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28554948/pubmed" id="28554948" target="_blank">28554948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8135249">
<a name="8135249"></a>Gales BJ, Gales MA. Erythema multiforme and angioedema with indapamide and sertraline. <i>Am J Hosp Pharm</i>. 1994;51(1):118‐119.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/8135249/pubmed" id="8135249" target="_blank">8135249</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19567656">
<a name="19567656"></a>Gareri P, Segura-García C, De Fazio P, De Fazio S, De Sarro G. Sertraline-induced rhabdomyolysis in an elderly patient with dementia and comorbidities. <i>Ann Pharmacother</i>. 2009;43(7):1354‐1359. doi:10.1345/aph.1M063<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/19567656/pubmed" id="19567656" target="_blank">19567656</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8185011">
<a name="8185011"></a>Ghaziuddin M. Mania induced by sertraline in a prepubertal child. <i>Am J Psychiatry</i>. 1994;151(6):944. doi:10.1176/ajp.151.6.944a<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/8185011/pubmed" id="8185011" target="_blank">8185011</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32215771">
<a name="32215771"></a>Gill N, Bayes A, Parker G. A review of antidepressant-associated hypomania in those diagnosed with unipolar depression-risk factors, conceptual models, and management. <i>Curr Psychiatry Rep</i>. 2020;22(4):20. doi:10.1007/s11920-020-01143-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/32215771/pubmed" id="32215771" target="_blank">32215771</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12243609">
<a name="12243609"></a>Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. <i>Ann Pharmacother</i>. 2002;36(10):1577-1589. doi:10.1345/aph.1A195<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/12243609/pubmed" id="12243609" target="_blank">12243609</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29522259">
<a name="29522259"></a>Grzeskowiak LE, Leggett C, Costi L, Roberts CT, Amir LH. Impact of serotonin reuptake inhibitor use on breast milk supply in mothers of preterm infants: a retrospective cohort study. <i>Br J Clin Pharmacol</i>. 2018;84(6):1373-1379. doi:10.1111/bcp.13575<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/29522259/pubmed" id="29522259" target="_blank">29522259</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23077009">
<a name="23077009"></a>Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. <i>Neurology</i>. 2012;79(18):1862‐1865. doi:10.1212/WNL.0b013e318271f848<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/23077009/pubmed" id="23077009" target="_blank">23077009</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11347722">
<a name="11347722"></a>Haddad PM. Antidepressant discontinuation syndromes. <i>Drug Saf</i>. 2001;24(3):183-197.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/11347722/pubmed" id="11347722" target="_blank">11347722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20807106">
<a name="20807106"></a>Hale TW, Kendall-Tackett K, Cong Z, et al, "Discontinuation Syndrome in Newborns Whose Mothers Took Antidepressants While Pregnant or Breastfeeding," <i>Breastfeed Med</i>, 2010, 5(6):283-288.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/20807106/pubmed" id="20807106" target="_blank">20807106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17506225">
<a name="17506225"></a>Halperin D, Reber G. Influence of antidepressants on hemostasis. <i>Dialogues Clin Neurosci</i>. 2007;9(1):47‐59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/17506225/pubmed" id="17506225" target="_blank">17506225</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16520440">
<a name="16520440"></a>Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. <i>Arch Gen Psychiatry</i>. 2006;63(3):332‐339. doi:10.1001/archpsyc.63.3.332<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16520440/pubmed" id="16520440" target="_blank">16520440</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29337001">
<a name="29337001"></a>Hathaway EE, Walkup JT, Strawn JR. Antidepressant Treatment Duration in Pediatric Depressive and Anxiety Disorders: How Long is Long Enough? <i>Curr Probl Pediatr Adolesc Health Care</i>. 2018;48(2):31-39.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/29337001/pubmed" id="29337001" target="_blank">29337001</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22012131">
<a name="22012131"></a>Hedayati SS, Yalamanchili V, Finkelstein FO. A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease. <i>Kidney Int</i>. 2012;81(3):247-255. doi:10.1038/ki.2011.358<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/22012131/pubmed" id="22012131" target="_blank">22012131</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28577352">
<a name="28577352"></a>Heller HM, Ravelli ACJ, Bruning AHL, et al. Increased postpartum haemorrhage, the possible relation with serotonergic and other psychopharmacological drugs: a matched cohort study. <i>BMC Pregnancy Childbirth</i>. 2017;17(1):166. doi:10.1186/s12884-017-1334-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28577352/pubmed" id="28577352" target="_blank">28577352</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23152227">
<a name="23152227"></a>Hetrick SE, McKenzie JE, Cox GR, Simmons MB, Merry SN. Newer generation antidepressants for depressive disorders in children and adolescents. <i>Cochrane Database Syst Rev</i>. 2012;11:CD004851. doi:10.1002/14651858.CD004851.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/23152227/pubmed" id="23152227" target="_blank">23152227</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2019">
<a name="Hirsch.2019"></a>Hirsch M, Birnbaum RJ. Discontinuing antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 29, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2018a">
<a name="Hirsch.2018a"></a>Hirsch M, Birnbaum RJ. Selective serotonin reuptake inhibitors: Pharmacology, administration, and side effects. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Hirsch.2018b">
<a name="Hirsch.2018b"></a>Hirsch M, Birnbaum RJ. Switching antidepressant medications in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed March 9, 2021b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30194278">
<a name="30194278"></a>Holmberg PJ, Arteaga G, Schiltz BM, Homme J. Sertraline-induced rhabdomyolysis, trismus, and cardiac arrest in a child. <i>Pediatrics</i>. 2018;142(4):e20180804. doi:10.1542/peds.2018-0804<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/30194278/pubmed" id="30194278" target="_blank">30194278</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31030620">
<a name="31030620"></a>Hudd TR, Blake CS, Rimola-Dejesus Y, Nguyen TT, Zaiken K. A case report of serotonin syndrome in a patient on selective serotonin reuptake inhibitor (SSRI) monotherapy. <i>J Pharm Pract</i>. 2020;33(2):206‐212. doi:10.1177/0897190019841742<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/31030620/pubmed" id="31030620" target="_blank">31030620</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19031644">
<a name="19031644"></a>Hussain HM, Zakaria M. Drug-induced lupus secondary to sertraline. <i>Aust N Z J Psychiatry</i>. 2008;42(12):1074‐1075.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/19031644/pubmed" id="19031644" target="_blank">19031644</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12534540">
<a name="12534540"></a>Isaksson M, Jansson L. Contact allergy to Tween 80 in an inhalation suspension. <i>Contact Dermatitis</i>. 2002;47(5):312-313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/12534540/pubmed" id="12534540" target="_blank">12534540</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27378473">
<a name="27378473"></a>Ismaili E, Walsh S, O'Brien PMS, et al. Fourth consensus of the International Society for Premenstrual Disorders (ISPMD): auditable standards for diagnosis and management of premenstrual disorder. <i>Arch Womens Ment Health</i>. 2016;19(6):953-958. doi:10.1007/s00737-016-0631-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/27378473/pubmed" id="27378473" target="_blank">27378473</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27249090">
<a name="27249090"></a>Issari Y, Jakubovski E, Bartley CA, Pittenger C, Bloch MH. Early onset of response with selective serotonin reuptake inhibitors in obsessive-compulsive disorder: a meta-analysis. <i>J Clin Psychiatry</i>. 2016;77(5):605-611. doi:10.4088/JCP.14r09758<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/27249090/pubmed" id="27249090" target="_blank">27249090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16896026">
<a name="16896026"></a>Jacob S, Spinler SA. Hyponatremia associated with selective serotonin-reuptake inhibitors in older adults. <i>Ann Pharmacother</i>. 2006;40(9):1618‐1622. doi:10.1345/aph.1G293<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16896026/pubmed" id="16896026" target="_blank">16896026</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10494732">
<a name="10494732"></a>Jan V, Toledano C, Machet L, Machet MC, Vaillant L, Lorette G. Stevens-Johnson syndrome after sertraline. <i>Acta Derm Venereol</i>. 1999;79(5):401. doi:10.1080/000155599750010472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/10494732/pubmed" id="10494732" target="_blank">10494732</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24314591">
<a name="24314591"></a>Jeong BO, Kim SW, Kim SY, Kim JM, Shin IS, Yoon JS. Use of serotonergic antidepressants and bleeding risk in patients undergoing surgery. <i>Psychosomatics</i>. 2014;55(3):213-220. doi:10.1016/j.psym.2013.08.011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/24314591/pubmed" id="24314591" target="_blank">24314591</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30501420">
<a name="30501420"></a>Jha MK, Rush AJ, Trivedi MH. When discontinuing SSRI antidepressants is a challenge: management tips. <i>Am J Psychiatry</i>. 2018;175(12):1176‐1184. doi:10.1176/appi.ajp.2018.18060692<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/30501420/pubmed" id="30501420" target="_blank">30501420</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24993365">
<a name="24993365"></a>Jiang HY, Chen HZ, Hu XJ, et al. Use of selective serotonin reuptake inhibitors and risk of upper gastrointestinal bleeding: a systematic review and meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2015;13(1):42‐50.e3. doi:10.1016/j.cgh.2014.06.021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/24993365/pubmed" id="24993365" target="_blank">24993365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29955469">
<a name="29955469"></a>Jing E, Straw-Wilson K. Sexual dysfunction in selective serotonin reuptake inhibitors (SSRIs) and potential solutions: a narrative literature review. <i>Ment Health Clin</i>. 2016;6(4):191‐196. doi:10.9740/mhc.2016.07.191<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/29955469/pubmed" id="29955469" target="_blank">29955469</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28796019">
<a name="28796019"></a>Karkow DC, Kauer JF, Ernst EJ. Incidence of serotonin syndrome with combined use of linezolid and serotonin reuptake inhibitors compared with linezolid monotherapy. <i>J Clin Psychopharmacol</i>. 2017;37(5):518-523. doi:10.1097/JCP.0000000000000751<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28796019/pubmed" id="28796019" target="_blank">28796019</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25081580">
<a name="25081580"></a>Katzman MA, Bleau P, Blier P, et al; Canadian Anxiety Guidelines Initiative Group. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. <i>BMC Psychiatry</i>. 2014;14(suppl 1):S1. doi:10.1186/1471-244X-14-S1-S1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/25081580/pubmed" id="25081580" target="_blank">25081580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23324513">
<a name="23324513"></a>Kaufman KR, Podolsky D, Greenman D, Madraswala R. Antidepressant-selective gynecomastia. <i>Ann Pharmacother</i>. 2013;47(1):e6. doi:10.1345/aph.1R491<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/23324513/pubmed" id="23324513" target="_blank">23324513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25964653">
<a name="25964653"></a>Kayhan F, Eken ZE, Uguz F. Sertraline-induced periorbital purpura: a case report. <i>Australas Psychiatry</i>. 2015;23(4):426‐428. doi:10.1177/1039856215586138<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/25964653/pubmed" id="25964653" target="_blank">25964653</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12668373">
<a name="12668373"></a>Khan A, Khan S, Kolts R, Brown WA. Suicide rates in clinical trials of SSRIs, other antidepressants, and placebo: analysis of FDA reports. <i>Am J Psychiatry</i>. 2003;160(4):790‐792. doi:10.1176/appi.ajp.160.4.790<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/12668373/pubmed" id="12668373" target="_blank">12668373</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22364401">
<a name="22364401"></a>Khan MA, Fitzgerald K. Low-dose sertraline-induced erythema multiforme in a child. <i>J Child Adolesc Psychopharmacol</i>. 2012;22(2):179‐180. doi:10.1089/cap.2011.0061<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/22364401/pubmed" id="22364401" target="_blank">22364401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30247774">
<a name="30247774"></a>Khanassov V, Hu J, Reeves D, van Marwijk H. Selective serotonin reuptake inhibitor and selective serotonin and norepinephrine reuptake inhibitor use and risk of fractures in adults: a systematic review and meta-analysis. <i>Int J Geriatr Psychiatry</i>. 2018;33(12):1688-1708. doi:10.1002/gps.4974<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/30247774/pubmed" id="30247774" target="_blank">30247774</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21487738">
<a name="21487738"></a>Khoza S, Barner JC. Glucose dysregulation associated with antidepressant agents: an analysis of 17 published case reports. <i>Int J Clin Pharm</i>. 2011;33(3):484‐492. doi:10.1007/s11096-011-9507-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/21487738/pubmed" id="21487738" target="_blank">21487738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27993931">
<a name="27993931"></a>Kirkham J, Seitz D. Evidence of ocular side effects of SSRIs and new warnings. <i>Evid Based Ment Health</i>. 2017;20(1):27. doi:10.1136/eb-2016-102528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/27993931/pubmed" id="27993931" target="_blank">27993931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7815874">
<a name="7815874"></a>Krivy J, Wiener J. Sertraline and platelet counts in idiopathic thrombocytopenia purpura. <i>Lancet</i>. 1995;345(8942):132. doi:10.1016/s0140-6736(95)90101-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/7815874/pubmed" id="7815874" target="_blank">7815874</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37160238">
<a name="37160238"></a>Kufel WD, Parsels KA, Blaine BE, Steele JM, Seabury RW, Asiago-Reddy EA. Real-world evaluation of linezolid-associated serotonin toxicity with and without concurrent serotonergic agents.<i> Int J Antimicrob Agents.</i> 2023;62(1):106843. doi:10.1016/j.ijantimicag.2023.106843<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/37160238/pubmed" id="37160238" target="_blank">37160238</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37645359">
<a name="37645359"></a>Kumar R, Ali SN, Saha S, Bhattacharjee S. SSRI induced hypnic jerks: a case series. <i>Indian J Psychiatry</i>. 2023;65(7):785-788. doi:10.4103/indianjpsychiatry.indianjpsychiatry_207_23<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/37645359/pubmed" id="37645359" target="_blank">37645359</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21407919">
<a name="21407919"></a>Kumar R, Dubey CK, Sinha VK. Sertraline induced hypomania. <i>Indian J Psychiatry</i>. 2000;42(1):104‐105.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/21407919/pubmed" id="21407919" target="_blank">21407919</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21948719">
<a name="21948719"></a>Labos C, Dasgupta K, Nedjar H, Turecki G, Rahme E. Risk of bleeding associated with combined use of selective serotonin reuptake inhibitors and antiplatelet therapy following acute myocardial infarction. <i>CMAJ</i>. 2011;183(16):1835-1843. doi:10.1503/cmaj.100912<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/21948719/pubmed" id="21948719" target="_blank">21948719</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10755580">
<a name="10755580"></a>Lake MB, Birmaher B, Wassick S, et al. Bleeding and Selective Serotonin Reuptake Inhibitors in Childhood and Adolescence. <i>J Child Adolesc Psychopharmacol</i>. 2000;10(1):35-38.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/10755580/pubmed" id="10755580" target="_blank">10755580</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31078196">
<a name="31078196"></a>Lanza di Scalea T, Pearlstein T. Premenstrual dysphoric disorder. <i>Med Clin North Am</i>. 2019;103(4):613-628. doi:10.1016/j.mcna.2019.02.007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/31078196/pubmed" id="31078196" target="_blank">31078196</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26344706">
<a name="26344706"></a>Larsen ER, Damkier P, Pedersen LH, et al. Use of psychotropic drugs during pregnancy and breast-feeding. <i>Acta Psychiatr Scand Suppl</i>. 2015;(445):1-28.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/26344706/pubmed" id="26344706" target="_blank">26344706</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18598735">
<a name="18598735"></a>Leombruni P, Pierò A, Lavagnino L, Brustolin A, Campisi S, Fassino S. A randomized double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with binge eating disorder. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2008;32(6):1599-1605.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/18598735/pubmed" id="18598735" target="_blank">18598735</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18056231">
<a name="18056231"></a>Leon AC. The revised warning for antidepressants and suicidality: unveiling the black box of statistical analyses. <i>Am J Psychiatry</i>. 2007;164(12):1786‐1789. doi:10.1176/appi.ajp.2007.07050775<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/18056231/pubmed" id="18056231" target="_blank">18056231</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16461873">
<a name="16461873"></a>Levinson-Castiel R, Merlob P, Linder N, et al. Neonatal Abstinence Syndrome After <i>in utero</i> Exposure to Selective Serotonin Reuptake Inhibitors in Term Infants. <i>Arch Pediatr Adolesc Med</i>. 2006;160(2):173-176.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16461873/pubmed" id="16461873" target="_blank">16461873</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18188866">
<a name="18188866"></a>Lewis JD, Strom BL, Localio AR, et al. Moderate and high affinity serotonin reuptake inhibitors increase the risk of upper gastrointestinal toxicity. <i>Pharmacoepidemiol Drug Saf</i>. 2008;17(4):328-335. doi:10.1002/pds.1546<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/18188866/pubmed" id="18188866" target="_blank">18188866</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8804257">
<a name="8804257"></a>Liu BA, Mittmann N, Knowles SR, Shear NH. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective serotonin reuptake inhibitors: a review of spontaneous reports [published correction appears in Can Med Assoc J 1996 Oct 15;155(8):1043]. <i>CMAJ</i>. 1996;155(5):519-527.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/8804257/pubmed" id="8804257" target="_blank">8804257</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17919277">
<a name="17919277"></a>Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. <i>Aliment Pharmacol Ther</i>. 2008;27(1):31‐40. doi:10.1111/j.1365-2036.2007.03541.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/17919277/pubmed" id="17919277" target="_blank">17919277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10985636">
<a name="10985636"></a>Lucente P, Iorizzo M, Pazzaglia M. Contact sensitivity to Tween 80 in a child. <i>Contact Dermatitis</i>. 2000;43(3):172.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/10985636/pubmed" id="10985636" target="_blank">10985636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27486149">
<a name="27486149"></a>MacQueen GM, Frey BN, Ismail Z, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder: Section 6. Special populations: youth, women, and the elderly. <i>Can J Psychiatry</i>. 2016;61(9):588-603. doi:10.1177/0706743716659276<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/27486149/pubmed" id="27486149" target="_blank">27486149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20680187">
<a name="20680187"></a>Madhusoodanan S, Alexeenko L, Sanders R, Brenner R. Extrapyramidal symptoms associated with antidepressants--a review of the literature and an analysis of spontaneous reports. <i>Ann Clin Psychiatry</i>. 2010;22(3):148‐156.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/20680187/pubmed" id="20680187" target="_blank">20680187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15057839">
<a name="15057839"></a>Malbergier A, de Oliveira Júnior HP. Sertraline and acute pancreatitis: a case-report [in Portuguese]. <i>Braz J Psychiatry</i>. 2004;26(1):39‐40. doi:10.1590/s1516-44462004000100011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15057839/pubmed" id="15057839" target="_blank">15057839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24094459">
<a name="24094459"></a>Mannesse CK, Jansen PA, Van Marum RJ, et al. Characteristics, prevalence, risk factors, and underlying mechanism of hyponatremia in elderly patients treated with antidepressants: a cross-sectional study. <i>Maturitas</i>. 2013;76(4):357‐363. doi:10.1016/j.maturitas.2013.08.010<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/24094459/pubmed" id="24094459" target="_blank">24094459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9842950">
<a name="9842950"></a>March JS, Biederman J, Wolkow R, et al. Sertraline in Children and Adolescents With Obsessive-Compulsive Disorder: A Multicenter Randomized Controlled Trial. <i>JAMA</i>. 1998;280(20):1752-1756.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/9842950/pubmed" id="9842950" target="_blank">9842950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10653222">
<a name="10653222"></a>Markowitz JS, DeVane CL. Rifampin-induced selective serotonin reuptake inhibitor withdrawal syndrome in a patient treated with sertraline. <i>J Clin Psychopharmacol</i>. 2000;20(1):109-110. doi:10.1097/00004714-200002000-00023<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/10653222/pubmed" id="10653222" target="_blank">10653222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19965920">
<a name="19965920"></a>Marshall AM, Nommsen-Rivers LA, Hernandez LL, et al. Serotonin Transport and Metabolism in the Mammary Gland Modulates Secretory Activation and Involution. <i>J Clin Endocrinol Metab</i>. 2010;95(2):837-846.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/19965920/pubmed" id="19965920" target="_blank">19965920</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15289250">
<a name="15289250"></a>Martin A, Young C, Leckman JF, Mukonoweshuro C, Rosenheck R, Leslie D. Age effects on antidepressant-induced manic conversion. <i>Arch Pediatr Adolesc Med</i>. 2004;158(8):773‐780. doi:10.1001/archpedi.158.8.773<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15289250/pubmed" id="15289250" target="_blank">15289250</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30170040">
<a name="30170040"></a>Masarwa R, Bar-Oz B, Gorelik E, Reif S, Perlman A, Matok I. Prenatal exposure to selective serotonin reuptake inhibitors and serotonin norepinephrine reuptake inhibitors and risk for persistent pulmonary hypertension of the newborn: a systematic review, meta-analysis, and network meta-analysis. <i>Am J Obstet Gynecol</i>. 2019;220(1):57.e1-57.e13. doi:10.1016/j.ajog.2018.08.030<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/30170040/pubmed" id="30170040" target="_blank">30170040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10941349">
<a name="10941349"></a>Mason PJ, Morris VA, Balcezak TJ. Serotonin syndrome. Presentation of 2 cases and review of the literature. <i>Medicine (Baltimore)</i>. 2000;79(4):201‐209. doi:10.1097/00005792-200007000-00001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/10941349/pubmed" id="10941349" target="_blank">10941349</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25248846">
<a name="25248846"></a>Mauri MC, Fiorentini A, Paletta S, Altamura AC. Pharmacokinetics of antidepressants in patients with hepatic impairment. <i>Clin Pharmacokinet</i>. 2014;53(12):1069-1081. doi:10.1007/s40262-014-0187-5<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/25248846/pubmed" id="25248846" target="_blank">25248846</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10831483">
<a name="10831483"></a>McElroy SL, Casuto LS, Nelson EB, et al. Placebo-controlled trial of sertraline in the treatment of binge eating disorder. <i>Am J Psychiatry</i>. 2000;157(6):1004-1006.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/10831483/pubmed" id="10831483" target="_blank">10831483</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9598491">
<a name="9598491"></a>McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride: a single-blind placebo controlled crossover study. <i>J Urol</i>. 1998a;159(6):1935-1938.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/9598491/pubmed" id="9598491" target="_blank">9598491</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9788108">
<a name="9788108"></a>McMahon CG. Treatment of premature ejaculation with sertraline hydrochloride. <i>Int J Impot Res</i>. 1998b;10(3):181-184; discussion 185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/9788108/pubmed" id="9788108" target="_blank">9788108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8830065">
<a name="8830065"></a>Mendels J, Camera A, Sikes C. Sertraline treatment for premature ejaculation. <i>J Clin Psychopharmacol</i>. 1995;15(5):341-346. doi:10.1097/00004714-199510000-00006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/8830065/pubmed" id="8830065" target="_blank">8830065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19652123">
<a name="19652123"></a>Meyers BS, Flint AJ, Rothschild AJ, et al; STOP-PD Group. A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD) [published correction appears in <i>Arch Gen Psychiatry</i>. 2011 Jun;68(6):626]. <i>Arch Gen Psychiatry</i>. 2009;66(8):838-847. doi:10.1001/archgenpsychiatry.2009.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/19652123/pubmed" id="19652123" target="_blank">19652123</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15605617">
<a name="15605617"></a>Milano W, Petrella C, Sabatino C, Capasso A. Treatment of bulimia nervosa with sertraline: a randomized controlled trial. <i>Adv Ther</i>. 2004;21(4):232-237.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15605617/pubmed" id="15605617" target="_blank">15605617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24566587">
<a name="24566587"></a>Moura C, Bernatsky S, Abrahamowicz M, et al. Antidepressant use and 10-year incident fracture risk: the population-based Canadian Multicentre Osteoporosis Study (CaMoS). <i>Osteoporos Int</i>. 2014;25(5):1473-1481. doi:10.1007/s00198-014-2649-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/24566587/pubmed" id="24566587" target="_blank">24566587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14581256">
<a name="14581256"></a>Movig KL, Janssen MW, de Waal Malefijt J, Kabel PJ, Leufkens HG, Egberts AC. Relationship of serotonergic antidepressants and need for blood transfusion in orthopedic surgical patients. <i>Arch Intern Med</i>. 2003;163(19):2354‐2358. doi:10.1001/archinte.163.19.2354<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/14581256/pubmed" id="14581256" target="_blank">14581256</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23249132">
<a name="23249132"></a>Müller MJ, Preuß C, Paul T, Streit F, Brandhorst G, Seeliger S. Serotonergic overstimulation in a preterm infant after sertraline intake via breastmilk. <i>Breastfeed Med</i>. 2013;8(3):327-329.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/23249132/pubmed" id="23249132" target="_blank">23249132</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17655517">
<a name="17655517"></a>Narita M, Tsuji BT, Yu VL. Linezolid-associated peripheral and optic neuropathy, lactic acidosis, and serotonin syndrome. <i>Pharmacotherapy.</i> 2007;27(8):1189-1197. doi:10.1592/phco.27.8.1189<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/17655517/pubmed" id="17655517" target="_blank">17655517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22132433">
<a name="22132433"></a>National Collaborating Centre for Mental Health (NCCMH). Depression: The Treatment and Management of Depression in Adults (Updated Edition). National Institute for Health &amp; Clinical Excellence (NICE). 2010.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/22132433/pubmed" id="22132433" target="_blank">22132433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2005">
<a name="NICE.2005"></a>National Institute for Health and Care Excellence (NICE). Obsessive-compulsive disorder and body dysmorphic disorder: treatment. https://www.nice.org.uk/guidance/cg31. Published November 2005. Accessed July 6, 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23624686">
<a name="23624686"></a>Nevatte T, O'Brien PM, Bäckström T, et al; Consensus Group of the International Society for Premenstrual Disorders. ISPMD consensus on the management of premenstrual disorders. <i>Arch Womens Ment Health</i>. 2013;16(4):279-291. doi:10.1007/s00737-013-0346-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/23624686/pubmed" id="23624686" target="_blank">23624686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14566197">
<a name="14566197"></a>Newport DJ, Stowe ZN. Clinical management of perinatal depression: focus on paroxetine. <i>Psychopharmacol Bull</i>. 2003;37(suppl 1):148-166.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/14566197/pubmed" id="14566197" target="_blank">14566197</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30407100">
<a name="30407100"></a>Ng QX, Venkatanarayanan N, Ho CYX, Sim WS, Lim DY, Yeo WS. Selective serotonin reuptake inhibitors and persistent pulmonary hypertension of the newborn: an update meta-analysis. <i>J Womens Health (Larchmt)</i>. 2019;28(3):331-338. doi:10.1089/jwh.2018.7319<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/30407100/pubmed" id="30407100" target="_blank">30407100</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16426083">
<a name="16426083"></a>Ninan PT, Koran LM, Kiev A, et al. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. <i>J Clin Psychiatry</i>. 2006;67(1):15-22.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16426083/pubmed" id="16426083" target="_blank">16426083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23459282">
<a name="23459282"></a>Ogle NR, Akkerman SR. Guidance for the discontinuation or switching of antidepressant therapies in adults. <i>J Pharm Pract</i>. 2013;26(4):389-396. doi:10.1177/0897190012467210.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/23459282/pubmed" id="23459282" target="_blank">23459282</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18460039">
<a name="18460039"></a>Opatrny L, Delaney JA, Suissa S. Gastro-intestinal haemorrhage risks of selective serotonin receptor antagonist therapy: a new look. <i>Br J Clin Pharmacol</i>. 2008;66(1):76‐81. doi:10.1111/j.1365-2125.2008.03154.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/18460039/pubmed" id="18460039" target="_blank">18460039</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25572308">
<a name="25572308"></a>Orsolini L, Bellantuono C. Serotonin reuptake inhibitors and breastfeeding: a systematic review. <i>Hum Psychopharmacol</i>. 2015;30(1):4-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/25572308/pubmed" id="25572308" target="_blank">25572308</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15994730">
<a name="15994730"></a>Ozcanli T, Unsalver B, Ozdemir S, Ozmen M. Sertraline- and mirtazapine-induced severe neutropenia. <i>Am J Psychiatry</i>. 2005;162(7):1386. doi:10.1176/appi.ajp.162.7.1386<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15994730/pubmed" id="15994730" target="_blank">15994730</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16415707">
<a name="16415707"></a>Papakostas GI, Perlis RH, Scalia MJ, Petersen TJ, Fava M. A meta-analysis of early sustained response rates between antidepressants and placebo for the treatment of major depressive disorder. <i>J Clin Psychopharmacol</i>. 2006;26(1):56-60. doi:10.1097/01.jcp.0000195042.62724.76<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16415707/pubmed" id="16415707" target="_blank">16415707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21768871">
<a name="21768871"></a>Patel NH, Golwala H, Stavrakis S, Schechter E. Sertraline-induced ventricular tachycardia. <i>Am J Ther</i>. 2013;20(6):e720‐e722. doi:10.1097/MJT.0b013e3182192d6e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/21768871/pubmed" id="21768871" target="_blank">21768871</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26667012">
<a name="26667012"></a>Patel R, Reiss P, Shetty H, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. <i>BMJ Open</i>. 2015;5(12):e008341. doi:10.1136/bmjopen-2015-008341<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/26667012/pubmed" id="26667012" target="_blank">26667012</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16150746">
<a name="16150746"></a>Paton C, Ferrier IN. SSRIs and gastrointestinal bleeding. <i>BMJ</i>. 2005;331(7516):529-530. doi:10.1136/bmj.331.7516.529<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16150746/pubmed" id="16150746" target="_blank">16150746</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28129551">
<a name="28129551"></a>Paulzen M, Goecke TW, Stickeler E, Gründer G, Schoretsanitis G. Sertraline in pregnancy - Therapeutic drug monitoring in maternal blood, amniotic fluid and cord blood. <i>J Affect Disord</i>. 2017;212:1-6. doi:10.1016/j.jad.2017.01.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28129551/pubmed" id="28129551" target="_blank">28129551</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15507582">
<a name="15507582"></a>Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. <i>JAMA</i>. 2004;292(16):1969-1976. doi:10.1001/jama.292.16.1969<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15507582/pubmed" id="15507582" target="_blank">15507582</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12772794">
<a name="12772794"></a>Persky S, Reinus JF. Sertraline hepatotoxicity: a case report and review of the literature on selective serotonin reuptake inhibitor hepatotoxicity. <i>Dig Dis Sci</i>. 2003;48(5):939‐944. doi:10.1023/a:1023007831047<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/12772794/pubmed" id="12772794" target="_blank">12772794</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Pfizer.2016">
<a name="Pfizer.2016"></a>Pfizer Medical Information, written communication, February 2, 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Phillips.2019">
<a name="Phillips.2019"></a>Phillips KA. Body dysmorphic disorder: Choosing treatment and prognosis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 8, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18325859">
<a name="18325859"></a>Phillips KA, Hollander E. Treating body dysmorphic disorder with medication: evidence, misconceptions, and a suggested approach. <i>Body Image</i>. 2008;5(1):13-27. doi:10.1016/j.bodyim.2007.12.003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/18325859/pubmed" id="18325859" target="_blank">18325859</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25589155">
<a name="25589155"></a>Pinheiro E, Bogen DL, Hoxha D, Ciolino JD, Wisner KL. Sertraline and breastfeeding: review and meta-analysis. <i>Arch Womens Ment Health</i>. 2015;18(2):139-146. doi:10.1007/s00737-015-0499-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/25589155/pubmed" id="25589155" target="_blank">25589155</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29557689">
<a name="29557689"></a>Pogliani L, Baldelli S, Cattaneo D, et al. Selective serotonin reuptake inhibitors' passage into human milk of lactating women. <i>J Matern Fetal Neonatal Med</i>. 2019;32(18):3020-3025. doi:10.1080/14767058.2018.1455180<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/29557689/pubmed" id="29557689" target="_blank">29557689</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9167832">
<a name="9167832"></a>Popli AP, Fuller MA, Jaskiw GE. Sertraline and psychotic symptoms: a case series. <i>Ann Clin Psychiatry</i>. 1997;9(1):15‐17. doi:10.1023/a:1026274123689<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/9167832/pubmed" id="9167832" target="_blank">9167832</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15704999">
<a name="15704999"></a>Posternak MA, Zimmerman M. Is there a delay in the antidepressant effect? A meta-analysis. <i>J Clin Psychiatry</i>. 2005;66(2):148-158. doi:10.4088/jcp.v66n0201<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15704999/pubmed" id="15704999" target="_blank">15704999</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35081579">
<a name="35081579"></a>Purohith AN, Chauhan A, Bhandary RP. Sertraline-associated burning mouth syndrome: a rare adverse effect of a frequently prescribed antidepressant. <i>J Clin Psychopharmacol</i>. 2022;42(3):315-316. doi:10.1097/JCP.0000000000001523<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/35081579/pubmed" id="35081579" target="_blank">35081579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22638709">
<a name="22638709"></a>Rabenda V, Nicolet D, Beaudart C, et al. Relationship between use of antidepressants and risk of fractures: a meta-analysis [published online ahead of print May 26, 2012]. <i>Osteoporos Int</i>. 2013;24(1):127-137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/22638709/pubmed" id="22638709" target="_blank">22638709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28766827">
<a name="28766827"></a>Rajasingham R, Meya DB, Boulware DR. Are fluconazole or sertraline dose adjustments necessary with concomitant rifampin? <i>HIV Med</i>. 2018;19(6):e64-e65. doi:10.1111/hiv.12543<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28766827/pubmed" id="28766827" target="_blank">28766827</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9818637">
<a name="9818637"></a>Rand EH. Priapism in a patient taking sertraline. <i>J Clin Psychiatry</i>. 1998;59(10):538. doi:10.4088/jcp.v59n1007e<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/9818637/pubmed" id="9818637" target="_blank">9818637</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26156519">
<a name="26156519"></a>Reefhuis J, Devine O, Friedman JM, Louik C, Honein MA; National Birth Defects Prevention Study. Specific SSRIs and birth defects: Bayesian analysis to interpret new data in the context of previous reports. <i>BMJ</i>. 2015;351:h3190. doi:10.1136/bmj.h3190<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/26156519/pubmed" id="26156519" target="_blank">26156519</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20553304">
<a name="20553304"></a>Reeves RR, Ladner ME. Antidepressant-induced suicidality: an update. <i>CNS Neurosci Ther</i>. 2010;16(4):227‐234. doi:10.1111/j.1755-5949.2010.00160.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/20553304/pubmed" id="20553304" target="_blank">20553304</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-manu.1">
<a name="manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17242321">
<a name="17242321"></a>Richards JB, Papaioannou A, Adachi JD, et al. Effect of selective serotonin reuptake inhibitors on the risk of fracture. <i>Arch Intern Med</i>. 2007;167(2):188‐194. doi:10.1001/archinte.167.2.188<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/17242321/pubmed" id="17242321" target="_blank">17242321</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22659406">
<a name="22659406"></a>Rizzoli R, Cooper C, Reginster JY, et al. Antidepressant medications and osteoporosis. <i>Bone</i>. 2012; 51(3):606-613.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/22659406/pubmed" id="22659406" target="_blank">22659406</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Rothschild.2019">
<a name="Rothschild.2019"></a>Rothschild AJ. Unipolar major depression with psychotic features: acute treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23979084">
<a name="23979084"></a>Sachs HC, Committee On Drugs. The transfer of drugs and therapeutics into human breast milk: an update on selected topics. <i>Pediatrics</i>. 2013;132(3):e796-809.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/23979084/pubmed" id="23979084" target="_blank">23979084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16553536">
<a name="16553536"></a>Safer DJ and Zito JM, "Treatment Emergent Adverse Effects of Selective Serotonin Reuptake Inhibitors by Age Group: Children vs. Adolescents,” <i>J Child Adolesc Psychopharmacol</i>, 2006, 16(1/2):159-69.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16553536/pubmed" id="16553536" target="_blank">16553536</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33113277">
<a name="33113277"></a>Sahan A, Cubuk A, Ozkaptan O, et al. Comparison of the safety and efficacy of the on-demand use of sertraline, dapoxetine, and daily use of sertraline in the treatment of patients with lifelong premature ejaculation: a prospective randomised study. <i>Andrologia</i>. 2020;52(11):e13854. doi:10.1111/and.13854<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/33113277/pubmed" id="33113277" target="_blank">33113277</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16683860">
<a name="16683860"></a>Schatzberg AF, Blier P, Delgado PL, et al. Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. <i>J Clin Psychiatry</i>. 2006;67(Suppl 4):27-30.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16683860/pubmed" id="16683860" target="_blank">16683860</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19530743">
<a name="19530743"></a>Schlatter C, Egger SS, Tchambaz L, Krähenbühl S. Pharmacokinetic changes of psychotropic drugs in patients with liver disease: implications for dose adaptation. <i>Drug Saf</i>. 2009;32(7):561-578. doi:10.2165/00002018-200932070-00003<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/19530743/pubmed" id="19530743" target="_blank">19530743</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32238008">
<a name="32238008"></a>Schoretsanitis G, Spigset O, Stingl JC, Deligiannidis KM, Paulzen M, Westin AA. The impact of pregnancy on the pharmacokinetics of antidepressants: a systematic critical review and meta-analysis. <i>Expert Opin Drug Metab Toxicol</i>. 2020;16(5):431-440. doi:10.1080/17425255.2020.1750598<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/32238008/pubmed" id="32238008" target="_blank">32238008</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8529300">
<a name="8529300"></a>Schwenk MH, Verga MA, Wagner JD. Hemodialyzability of sertraline. <i>Clin Nephrol</i>. 1995;44(2):121-124.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/8529300/pubmed" id="8529300" target="_blank">8529300</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Sertraline capsule [prescribing information]. Morristown, NJ: Almatica Pharma LLC; August 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17163258">
<a name="17163258"></a>Sharp SC, Hellings JA. Efficacy and Safety of Selective Serotonin Reuptake Inhibitors in the Treatment of Depression in Children and Adolescents: Practitioner Review. <i>Clin Drug Investig</i>. 2006;26(5):247-255.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/17163258/pubmed" id="17163258" target="_blank">17163258</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7746084">
<a name="7746084"></a>Shelley WB, Talanin N, Shelley ED. Polysorbate 80 hypersensitivity. <i>Lancet</i>. 1995;345(8980):1312-1313.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/7746084/pubmed" id="7746084" target="_blank">7746084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15014601">
<a name="15014601"></a>Shelton, RC. Steps following attainment of remission: discontinuation of antidepressant therapy. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3(4):168-174.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15014601/pubmed" id="15014601" target="_blank">15014601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34961344">
<a name="34961344"></a>Shindel AW, Althof SE, Carrier S, et al. Disorders of ejaculation: an AUA/SMSNA guideline. <i>J Urol</i>. 2022;207(3):504-512. doi:10.1097/JU.0000000000002392<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/34961344/pubmed" id="34961344" target="_blank">34961344</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Simon.2016">
<a name="Simon.2016"></a>Simon G. Unipolar major depression in adults: Choosing initial treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 20, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31808410">
<a name="31808410"></a>Siroosbakht S, Rezakhaniha S, Rezakhaniha B. Which of available selective serotonin reuptake inhibitors (SSRIs) is more effective in treatment of premature ejaculation? A randomized clinical trial. <i>Int Braz J Urol</i>. 2019;45(6):1209-1215. doi:10.1590/S1677-5538.IBJU.2019.0121<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/31808410/pubmed" id="31808410" target="_blank">31808410</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15185271">
<a name="15185271"></a>Sloan DM, Mizes JS, Helbok C, Muck R. Efficacy of sertraline for bulimia nervosa. <i>Int J Eat Disord</i>. 2004;36(1):48-54.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15185271/pubmed" id="15185271" target="_blank">15185271</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31035856">
<a name="31035856"></a>Slomian J, Honvo G, Emonts P, Reginster JY, Bruyère O. Consequences of maternal postpartum depression: a systematic review of maternal and infant outcomes. <i>Womens Health (Lond)</i>. 2019;15:1745506519844044. doi:10.1177/1745506519844044<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/31035856/pubmed" id="31035856" target="_blank">31035856</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29210786">
<a name="29210786"></a>Smith MM, Smith BB, Lahr BD, et al. Selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors are not associated with bleeding or transfusion in cardiac surgical patients. <i>Anesth Analg</i>. 2018;126(6):1859‐1866. doi:10.1213/ANE.0000000000002668<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/29210786/pubmed" id="29210786" target="_blank">29210786</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26204124">
<a name="26204124"></a>Sriraman NK, Melvin K, Meltzer-Brody S. ABM clinical protocol #18: use of antidepressants in breastfeeding mothers. <i>Breastfeed Med</i>. 2015;10(6):290-299.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/26204124/pubmed" id="26204124" target="_blank">26204124</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10333979">
<a name="10333979"></a>Stahl SM. Mechanism of action of serotonin selective reuptake inhibitors. Serotonin receptors and pathways mediate therapeutic effects and side effects. <i>J Affect Disord</i>. 1998;51(3):215‐235. doi:10.1016/s0165-0327(98)00221-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/10333979/pubmed" id="10333979" target="_blank">10333979</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.2018">
<a name="Stein.2018"></a>Stein MB. Management of posttraumatic stress disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2022b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Stein.2019">
<a name="Stein.2019"></a>Stein MB. Pharmacotherapy for social anxiety disorder in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 17, 2022a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18628446">
<a name="18628446"></a>Stevens DL. Association between selective serotonin-reuptake inhibitors, second-generation antipsychotics, and neuroleptic malignant syndrome. <i>Ann Pharmacother</i>. 2008;42(9):1290-1297.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/18628446/pubmed" id="18628446" target="_blank">18628446</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12590627">
<a name="12590627"></a>Stowe ZN, Hostetter AL, Owens MJ, et al. The Pharmacokinetics of Sertraline Excretion Into Human Breast Milk: Determinants of Infant Serum Concentrations. <i>J Clin Psychiatry</i>. 2003;64(1):73-80.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/12590627/pubmed" id="12590627" target="_blank">12590627</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9286185">
<a name="9286185"></a>Stowe ZN, Owens MJ, Landry JC, et al. Sertraline and Desmethylsertraline in Human Breast Milk and Nursing Infants. <i>Am J Psychiatry</i>. 1997;154(9):1255-1260.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/9286185/pubmed" id="9286185" target="_blank">9286185</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18759711">
<a name="18759711"></a>Sun-Edelstein C, Tepper SJ, Shapiro RE. Drug-induced serotonin syndrome: a review. <i>Expert Opin Drug Saf</i>. 2008;7(5):587‐596. doi:10.1517/14740338.7.5.587<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/18759711/pubmed" id="18759711" target="_blank">18759711</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30676405">
<a name="30676405"></a>Sylvester C, Menke M, Gopalan P. Selective serotonin reuptake inhibitors and fertility: considerations for couples trying to conceive. <i>Harv Rev Psychiatry</i>. 2019;27(2):108-118. doi:10.1097/HRP.0000000000000204<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/30676405/pubmed" id="30676405" target="_blank">30676405</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sysko.2019">
<a name="Sysko.2019"></a>Sysko R, Devlin M. Binge eating disorder in adults: Overview of treatment. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 7, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19254516">
<a name="19254516"></a>Szegedi A, Jansen WT, van Willigenburg AP, van der Meulen E, Stassen HH, Thase ME. Early improvement in the first 2 weeks as a predictor of treatment outcome in patients with major depressive disorder: a meta-analysis including 6562 patients. <i>J Clin Psychiatry</i>. 2009;70(3):344-353. doi:10.4088/jcp.07m03780<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/19254516/pubmed" id="19254516" target="_blank">19254516</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19491861">
<a name="19491861"></a>Targownik LE, Bolton JM, Metge CJ, Leung S, Sareen J. Selective serotonin reuptake inhibitors are associated with a modest increase in the risk of upper gastrointestinal bleeding. <i>Am J Gastroenterol</i>. 2009;104(6):1475‐1482. doi:10.1038/ajg.2009.128<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/19491861/pubmed" id="19491861" target="_blank">19491861</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16779744">
<a name="16779744"></a>Taylor JJ, Wilson JW, Estes LL. Linezolid and serotonergic drug interactions: a retrospective survey. <i>Clin Infect Dis</i>. 2006;43(2):180-187. doi:10.1086/504809<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16779744/pubmed" id="16779744" target="_blank">16779744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11140782">
<a name="11140782"></a>Thomsen PH. Obsessive-Compulsive Disorder: Pharmacological Treatment. <i>Eur Child Adolesc Psychiatry.</i> 2000;9(suppl 1):I76-184.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/11140782/pubmed" id="11140782" target="_blank">11140782</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28766108">
<a name="28766108"></a>Tomlin AM, Reith DM, Woods DJ, et al. A pharmacoepidemiology database system for monitoring risk due to the use of medicines by New Zealand primary care patients. <i>Drug Saf</i>. 2017;40(12):1259‐1277. doi:10.1007/s40264-017-0579-1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28766108/pubmed" id="28766108" target="_blank">28766108</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19958306">
<a name="19958306"></a>Tondo L, Vázquez G, Baldessarini RJ. Mania associated with antidepressant treatment: comprehensive meta-analytic review. <i>Acta Psychiatr Scand</i>. 2010;121(6):404‐414. doi:10.1111/j.1600-0447.2009.01514.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/19958306/pubmed" id="19958306" target="_blank">19958306</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8935613">
<a name="8935613"></a>Trescoli-Serrano C, Smith NK. Sertraline-induced agranulocytosis. <i>Postgrad Med J</i>. 1996;72(849):446. doi:10.1136/pgmj.72.849.446<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/8935613/pubmed" id="8935613" target="_blank">8935613</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27575664">
<a name="27575664"></a>Uguz F, Arpaci N. Short-term safety of paroxetine and sertraline in breastfed infants: a retrospective cohort study from a university hospital. <i>Breastfeed Med</i>. 2016;11:487-489.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/27575664/pubmed" id="27575664" target="_blank">27575664</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-VADod.2017">
<a name="VADod.2017"></a>US Department of Veterans Affairs/Department of Defense (VA/DoD). VA/DoD clinical practice guideline for the management of posttraumatic stress disorder and acute stress disorder. <a href="https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf" target="_blank">https://www.healthquality.va.gov/guidelines/MH/ptsd/VADoDPTSDCPGFinal012418.pdf</a> Updated June 2017. Accessed December 2017.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15906018">
<a name="15906018"></a>van Geffen EC, Hugtenburg JG, Heerdink ER, van Hulten RP, Egberts AC. Discontinuation symptoms in users of selective serotonin reuptake inhibitors in clinical practice: tapering versus abrupt discontinuation. <i>Eur J Clin Pharmacol</i>. 2005;61(4):303-307. doi:10.1007/s00228-005-0921-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15906018/pubmed" id="15906018" target="_blank">15906018</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28622213">
<a name="28622213"></a>Varela Piñón M, Adán-Manes J. Selective serotonin reuptake inhibitor-induced hyponatremia: clinical implications and therapeutic alternatives. <i>Clin Neuropharmacol</i>. 2017;40(4):177‐179. doi:10.1097/WNF.0000000000000221<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28622213/pubmed" id="28622213" target="_blank">28622213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27663940">
<a name="27663940"></a>Varigonda AL, Jakubovski E, Bloch MH. Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder. <i>J Am Acad Child Adolesc Psychiatry</i>. 2016;55(10):851-859.e2. doi:10.1016/j.jaac.2016.07.768<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/27663940/pubmed" id="27663940" target="_blank">27663940</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11129758">
<a name="11129758"></a>Verrico MM, Nace DA, Towers AL. Fulminant chemical hepatitis possibly associated with donepezil and sertraline therapy. <i>J Am Geriatr Soc</i>. 2000;48(12):1659‐1663. doi:10.1111/j.1532-5415.2000.tb03879.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/11129758/pubmed" id="11129758" target="_blank">11129758</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18219438">
<a name="18219438"></a>Vestergaard P, Rejnmark L, Mosekilde L. Selective serotonin reuptake inhibitors and other antidepressants and risk of fracture. <i>Calcif Tissue Int</i>. 2008;82(2):92-101. doi:10.1007/s00223-007-9099-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/18219438/pubmed" id="18219438" target="_blank">18219438</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34928566">
<a name="34928566"></a>Viani I, Meyer F. Intermittent electric shock-like sensations associated with sertraline use for treatment of obsessive-compulsive disorder. <i>J Clin Psychopharmacol</i>. 2022;42(1):101-103. doi:10.1097/JCP.0000000000001472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/34928566/pubmed" id="34928566" target="_blank">34928566</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31862812">
<a name="31862812"></a>Virdee G, Bleasdale J, Ikramullah M, Graham-Clarke E. Sertraline-induced hypersensitivity pneumonitis. <i>BMJ Case Rep</i>. 2019;12(12):e230724. doi:10.1136/bcr-2019-230724<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/31862812/pubmed" id="31862812" target="_blank">31862812</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30775508">
<a name="30775508"></a>Wadhwa R, Kumar M, Talegaonkar S, Vohora D. Serotonin reuptake inhibitors and bone health: a review of clinical studies and plausible mechanisms. <i>Osteoporos Sarcopenia</i>. 2017;3(2):75‐81. doi:10.1016/j.afos.2017.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/30775508/pubmed" id="30775508" target="_blank">30775508</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15908090">
<a name="15908090"></a>Wagner KD. Pharmacotherapy for Major Depression in Children and Adolescents. <i>Prog Neuropsychopharmacol Biol Psychiatry</i>. 2005;29(5):819-826.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15908090/pubmed" id="15908090" target="_blank">15908090</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12941675">
<a name="12941675"></a>Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. <i>JAMA</i>. 2003;290(8):1033-1041. doi:10.1001/jama.290.8.1033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/12941675/pubmed" id="12941675" target="_blank">12941675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26003261">
<a name="26003261"></a>Waldinger MD. Psychiatric disorders and sexual dysfunction. <i>Handb Clin Neurol</i>. 2015;130:469‐489. doi:10.1016/B978-0-444-63247-0.00027-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/26003261/pubmed" id="26003261" target="_blank">26003261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32439401">
<a name="32439401"></a>Walter HJ, Bukstein OG, Abright AR, et al. Clinical practice guideline for the assessment and treatment of children and adolescents with anxiety disorders. <i>J Am Acad Child Adolesc Psychiatry</i>. 2020;59(10):1107-1124. doi:10.1016/j.jaac.2020.05.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/32439401/pubmed" id="32439401" target="_blank">32439401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16913164">
<a name="16913164"></a>Warner, CH, Bobo W, Warner C, Reid S, Rachal J. Antidepressant discontinuation syndrome. <i>Am Fam Physician</i>. 2006;74(3):449-456.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/16913164/pubmed" id="16913164" target="_blank">16913164</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15169695">
<a name="15169695"></a>Weissman AM, Levy BT, Hartz AJ, et al. Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants. <i>Am J Psychiatry</i>. 2004;161(6):1066-1078. doi:10.1176/appi.ajp.161.6.1066<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/15169695/pubmed" id="15169695" target="_blank">15169695</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29873955">
<a name="29873955"></a>Williams AJ, Lai Z, Knight S, Kamali M, Assari S, McInnis MG. Risk factors associated with antidepressant exposure and history of antidepressant-induced mania in bipolar disorder. <i>J Clin Psychiatry</i>. 2018;79(3):17m11765. doi:10.4088/JCP.17m11765<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/29873955/pubmed" id="29873955" target="_blank">29873955</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28953843">
<a name="28953843"></a>Womersley K, Ripullone K, Agius M. What are the risks associated with different selective serotonin re-uptake inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence. <i>Psychiatr Danub</i>. 2017;29(suppl 3):629-644.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/28953843/pubmed" id="28953843" target="_blank">28953843</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31169738">
<a name="31169738"></a>Yi ZM, Chen SD, Tang QY, Tang HL, Zhai SD. Efficacy and safety of sertraline for the treatment of premature ejaculation: systematic review and meta-analysis. <i>Medicine (Baltimore)</i>. 2019;98(23):e15989. doi:10.1097/MD.0000000000015989<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/31169738/pubmed" id="31169738" target="_blank">31169738</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19701065">
<a name="19701065"></a>Yonkers KA, Wisner KL, Stewart DE, et al. The management of depression during pregnancy: a report from the American Psychiatric Association and the American College of Obstetricians and Gynecologists. <i>Obstet Gynecol</i>. 2009;114(3):703-713.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/19701065/pubmed" id="19701065" target="_blank">19701065</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26351969">
<a name="26351969"></a>Yonkers KA, Kornstein SG, Gueorguieva R, Merry B, Van Steenburgh K, Altemus M. Symptom-onset dosing of sertraline for the treatment of premenstrual dysphoric disorder: a randomized clinical trial. <i>JAMA Psychiatry</i>. 2015;72(10):1037-1044. doi:10.1001/jamapsychiatry.2015.1472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/sertraline-pediatric-drug-information/abstract-text/26351969/pubmed" id="26351969" target="_blank">26351969</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Zoloft.2019.05">
<a name="Zoloft.2019.05"></a>Zoloft (sertraline) [prescribing information]. New York, NY: Pfizer; October 2021.</div>
</li>
<li>
<div class="reference">
                  Zoloft (sertraline) [prescribing information]. Morgantown, WV: Viatris Specialty LLC; August 2023.</div>
</li></ol></div><div id="topicVersionRevision">Topic 12787 Version 651.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
